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ABSTRACT
Cell signaling translates extracellular signals into intracellular processes that carry
out cellular functions. The introduction of artificial signaling networks using synthetic
biology methods has facilitated the investigation of signaling mechanisms and the
generation of novel cell functions. Several synthetic biology methods that are based on
chemical controls have been developed to provide precise temporal regulation. In my
dissertation, we constructed new synthetic biology engineering strategies to control
tailored cellular events.

Described in Chapter 2, we developed a new chemical strategy to generate de novo
signaling pathways that link a signaling molecule, H2O2, to different downstream
cellular events in mammalian cells. This approach combines the reactivity-based H2O2
sensing with the chemically induced proximity (CIP) technology. By chemically
modifying a CIP inducer, abscisic acid (ABA), with an H2O2-sensitive boronate ester
probe, novel H2O2 signaling pathways were engineered to induce transcription, protein
translocation and membrane ruffle formation upon exogenous or endogenous H2O2
stimulation. This strategy has also been successfully applied to gibberellic acid (GA)based CIP system, which provides the potential to build signaling networks based on
orthogonal cell stimuli.

Encouraged from development of the H2O2-based strategy, described in chapter 3,
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we developed another new synthetic biology strategy which integrated chemical
reactivity sensing and CIP methods to generate artificial Fe2+ signaling circuitry to
control tailored cellular events in mammalian cells. A new probe ABA-FE18 (Fe2+sensing and protein dimerization) derived from ABA was developed and used to control
gene activation, signal transduction, and cytoskeletal remodeling in response to Fe2+.
Combining Fe2+ and H2O2 sensing with ABA and GA CIP systems, signal circuitries
were designed to implement “AND” and “OR” biologic gates that enables mammalian
cells to convert different combinations of Fe2+ and H2O2 signals into pre-defined
biological outputs.

Described in the last chapter, we engineered a unique CIP method based on mutant
antibody VL domain using a fluorogenic malachite green derivative as the inducer,
which gives fluorescent signals upon VL domain dimerization while simultaneously
inducing downstream biological effects.
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Chapter 1
Introduction
1.1 Synthetic signaling pathways and cellular functions

Synthetic biology aims to engineer and assemble predictable biological “parts” to
create tailored cells that transmission information and generate novel functions.1 One
of the focus in mammalian synthetic biology is to engineer signal transduction, which
allows cells to convert (and amplify) external stimuli in cellular environment into
proper cellular responses (Figure 1.1).3,4

Figure 1.1 Principles of signal transduction pathway2

1

The signal transduction processes typically are constituted of 3 major steps: sensing,
processing and actuation. The sensing step employs various mechanisms to perceive
environmental signals, such as surrounding chemicals, light, heat, nucleic acids,
antigens or pH. In the processing step, these detected signals are integrated and
combinatorically processed via internal logic circuits to reach decisions that are coupled
to the production of different biological outputs in the actuation step (Figure 1.2).5-7

Figure 1.2 Designing customized cell signaling responses by harnessing the
inherent modularity of cell signaling and gene regulatory networks7

Various efforts in synthetic biology research have been dedicated to engineer
predictable and tailored cellular functions in response to detected stimuli by rewiring
or creating synthetic signal transduction pathways.8-10 To create a synthetic signaling
pathway, one needs to consider how to create sensing units that can recognize only the
chosen signals, how to transmit and process the detected signals, and how to link a
processed decision to desired functional outputs. Most of the current methods to

2

engineer synthetic signaling pathways rely on either rewiring nature-evolved pathways
or creating de novo synthetic pathways by evolving and selecting novel signaling parts.6
The first approach requires extensive knowledge of native cell signaling pathways and
is limited to existing pathways in nature. The second approach can potentially provide
unlimited possibility in constructing new signaling pathways. However, it requires
substantial efforts and may still not obtain functional products as desired. The
engineering information that is gained is also less likely to be transferable to the design
of a new signaling component. In my thesis, I developed an alternative chemistryintegrated synthetic biology strategy combining chemically induced proximity (CIP)
and reactivity-based signal sensing methods to engineering novel signaling pathways.

1.2 Chemically induced proximity

The CIP methods, or chemically induced dimerization (CID), use small moleculeinducers to control the homo- or hetero-dimerization of two proteins (Figure 1.3). The
small molecule dimerizers either bind to both corresponding proteins simultaneously or
bind one of the proteins to induce a conformational change that leads to the binding of
the second protein. Each CIP inducer triggers the association between two unique
inducer-binding adaptor proteins that are typically fused individually to two other
proteins of interest (POIs). Depending on the choice of POIs, various downstream
biological events can be linked to the stimulation of these exogenous inducers,11-13
which provide a rapid and modular way to create novel CIP inducer-responsive
3

synthetic cellular functions and signaling pathways (Figure 1.4).

Figure 1.3 General principle of chemically induced dimerization (CID). In the
presence of a symmetrical ligand, two proteins can be brought together to form a
homodimer (A). With a nonsymmetrical ligand, two different proteins can be
brought together to form a heterodimer (B)11.

Figure 1.4 Strategies used in CIP: reconstitution of functional proteins/domains
(A), inducing proximity between proteins (B), controlling protein localization (C),

4

modulation of protein or small molecule activities by recruiting endogenous
protein (D).14

The CIP systems have been proven to be useful and versatile tools for biological
research and biomedical applications. The concept of CIP was inspired from the
discovery that the immunosuppressive activity of FK506 stem from the FK506-induced
dimerization between FKBP12 and calcineurin. A homo-dimerization system using
FK1012 (that links 2 FK506) to dimerize two FKBP12-fusion proteins was introduced
by Schreiber, Crabtree and coworkers.15 In this study, FK1012 was used to activate the
endogenous signal transduction cascade by fusing FKBP12 to the proximity regulated
ζ-chain of the T-cell receptor (Figure 1.5).

5

Figure 1.5 Initial demonstration of the CID concept. On the left, two FKBP
monomers bind the bivalent drug FK1012. On the right, FKBP-TCR fusion
proteins are dimerized by FK1012, initiating intracellular signaling.15

In the following years, multiple orthogonal CIP systems using different chemical
inducers, including rapamycin, abscisic acid (ABA), gibberellic acid (GA) and other
synthetic ligands

11, 14, 16

have been developed and applied in broad biological

applications. Several dimerization systems have been derived from plant signaling
systems. Plant hormones involved in these systems are readily available, inexpensive
and often nontoxic as they do not have homologous partner in mammalian cells.

Figure 1.6 The structure of ABA (a) and the X-ray crystal structure of PYL1-ABAABI1(b).14

6

One of the plant hormone-based CIP systems is engineered from the ABA signaling
pathway.17 ABA (Figure 1.6a) is a small molecule plant hormone that controls the stress
responses when plants face drought or extreme temperature and regulate plant growth
and development such as leaf abscission. Figure 1.6b shows the X-ray structures of
PYL1-ABA-ABI1: The PYL protein contains two flexible loops that are open in the
absence of ABA. In the presence of ABA, PYL binds to ABA with these two loops
closed to totally enclose ABA, which creates an extensive complementary surface that
can bind another protein ABI1.

Another example of the plant hormone-based CIP is engineered based on the GA
signaling pathway.13 As shows in Figure 1.7, a modified GA, GA3-AM, can cross the
cell membrane and be processed by cytosolic esterase to release free GA3. GA3 then
binds GID1 (blue), which induces formation of a complex between GID1 and GAI (red).

7

Figure 1.7 General scheme of gibberellin-induced CID used in this study.13

1.3 Reaction-based small-molecule probes

Many reaction-based small-molecule fluorescent probes have been developed to
report the existence or levels of specific cellular species in living cells with minimal
perturbation.18-19 These probes have unique “signal-sensing” units conjugated to the
fluorophores and remain non-fluorescent until they are exposed to specific signals, for
example, endogenous cellular signaling molecules (e.g. H2O2, H2S, O3), metal ions (e.g.
Hg2+, Cu+, Co2+, Fe2+) 19 or specific pH value (Figure 1.8). These tools not only help
decipher the roles of these probed molecules in cells, they also find applications in
diagnostics for human diseases that differentiate between the normal and disease tissues
by probing molecules that are signature of pathological conditions.20-21 It is possible to
conjugate the “signal sensing” chemical moieties with therapeutic molecules to achieve
the selective release of drugs in or around diseased tissues. We expect that these signal
sensing units can be used to cage CIP inducers that allows the control of protein
dimerization and associated downstream cellular effects to be regulated by specific
cellular signals.

8

Figure 1.8 Some examples for reaction-based small-molecule fluorescent probes.19

1.4 My thesis project

My PhD research aims to develop alternative synthetic biology strategies that are
chemistry-based and allow rapid and modular construction of new signaling pathways
with unique signal responding specificity and giving tailored biological outputs. It
integrated the CIP technology and reactivity-based signal sensing methods. My goal is
to combine CIP system with existing and new reactivity-based chemical probes to
enable the controls of biological processes by user-chosen cell signals (eg., H2O2 and
Fe2+) in living cells. This approach should be versatile in generating new signaling
pathways and controlling biological systems by changing the signal sensing probes or
the CIP protein components according to specific needs. This strategy can be used to
9

create biological computing systems in mammalian cells which can translate different
combinations of cell signals into pre-defined biological outputs. These works will be
described in detail in Chapter 2 and Chapter 3. To expand the available CIP toolbox and
create a new “self-reporting” CIP method, we developed a new CIP system based on
fluorogenic Malachite Green derivatives, where the dimerization process can be
monitored through the fluorescence changes, and different downstream biological
processes can be induced through protein dimerization. This work will be described in
Chapter 4.
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Chapter 2
Constructing de novo H2O2 Signaling via Induced Protein Proximity
(Reproduced with permission from

ACS Chemical Biology 2015, 10(6), 1404−1410

Copyright © 2015 American Society.

The other authors, Roushu Zhang, Weimin Xuan, are acknowledged.

Supporting information of the publication is incorporated in this chapter)

2.1 Introduction

Nature evolves sophisticated cell signaling circuits that convert perceived
environmental signals into proper cellular responses to maintain normal function of
cells. Recent efforts have been dedicated to engineer predictable and tailored cellular
functions in response to detected stimuli by rewiring or creating synthetic signal
transduction pathways.1-3 These efforts contribute to the understanding of how
sophisticated cellular functions and behaviors are built and hold great promise for
biological computing4-5 and novel therapeutic applications.6-7

14

To create a synthetic signaling pathway, one needs to consider how to create a
sensing unit that can recognize only the chosen signal, how to transmit and process the
detected signal, and how to link a processed decision to a desired functional output.
Most of the current methods to engineer synthetic pathways that respond to cellular
signals rely on either rewiring nature-evolved pathways or creating de novo synthetic
pathways by evolving and selecting novel signaling parts.8 The first approach requires
extensive knowledge of native cell signaling pathways and is limited to existing
pathways in nature. The second approach can potentially provide unlimited possibility
in constructing new signaling pathways. However, it requires substantial efforts and
may still not obtain functional products as desired. The engineering information that is
gained is also less likely to be transferable to the design of a new signaling component.

The chemically induced proximity (CIP), or chemically induced dimerization
(CID), technology has been developed to regulate biological processes using exogenous
chemical inducers.9 Each CIP inducer triggers the association between two unique
inducer-binding adaptor proteins that are fused individually to two other proteins of
interest (POIs). Depending on the choice of POIs, various downstream biological
events can be linked to the stimulation of these exogenous inducers,10-12 which provide
a rapid and modular way to create novel CIP inducer-responsive synthetic signaling
pathways. This technology provides a rapid and modular way to create novel CIP
inducer-responsive synthetic signaling pathways. Several orthogonal CIP systems using
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different chemical inducers, including rapamycin, abscisic acid (ABA), gibberellic acid
(GA), and other synthetic ligands,10, 13-14 have been developed for broad biological
applications.

H2O2 is a member of the reactive oxygen species (ROS) and an important diffusible
secondary messenger in biological systems.15 It plays critical roles in several biological
processes (e.g., signal transduction, cell differentiation, and apoptosis) and human
diseases (e.g., cancer and neurodegenerative diseases).16-20 Here, we report a novel
chemical strategy to create de novo H2O2 signaling pathways that can be tailored to
give desired downstream biological outcomes by integrating the CIP methods and the
H2O2 sensing technology. We showed that new signaling pathways can be engineered
to link the H2O2 signal to otherwise unrelated cellular processes, including expression
of chosen genes, translocation of chosen proteins, and remodeling of cytoskeleton
through activating endogenous Rac1 signaling.

Figure 2.1 General process for H2O2-induced proximity to control biological processes.
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In the design of an H2O2-signaling inducer, an H2O2 responsive masking group is
incorporated into a CIP inducer to abolish the protein dimerization ability of the inducer.
It is expected that the modified inducer remains inactive until being exposed to H2O2.
H2O2 then promotes the chemical cleavage of the masking group to regenerate the
original CIP inducer that triggers the predesigned biological effects (Figure 2.1).

2.2 Design and application of ABA-HP

To explore the feasibility of this strategy, we first focused on the ABA CIP system
that we developed.13 ABA binds selectively to the PYL protein and causes a
conformational change of PYL to create a surface that can subsequently bind the ABI
protein. On the basis of the crystal structure, ABA is totally embedded within the PYL
pocket where it makes extensive contacts.21 We hypothesize that any chemical
modification of ABA will likely disrupt its binding to PYL and therefore abolish the
induced association between PYL and ABI. By modifying ABA with a chemical moiety
that can be removed by H2O2, the ABA-based CIP activity should then be controlled by
H2O2. We have recently shown that modifications at the carboxylic acid group on ABA,
which engages in critical hydrogen bonding to PYL,21 disrupted the CIP activity of the
caged ABA.22 We expect that a similar strategy can be used to install an H2O2-sensing
unit onto ABA to mask its CIP activity. Several H2O2-responsive fluorescent probes
have been developed.23 H2O2-inducible systems that control transcription or cellular
targeting were also reported.24-25 In these studies, a boronate ester moiety was used as
17

the H2O2-sensing unit. We reason that when ABA is equipped with the same boronate
ester moiety, the ABA inducible CIP should then be controlled by H2O2.

2.2.1 Synthesis and HPLC test of ABA-HP

To examine the feasibility of this strategy, we synthesized an H2O2-responsive
boronate-conjugated ABA, referred to as ABA-HP (Figure 2.2), which is expected to
convert back to ABA upon the exposure to H2O2 based on a reported oxidative cleavage
mechanism (Figure 2.3).23

Figure 2.2 Synthesis of ABA-HP and its conversion to ABA in the presence of H2O2.
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Figure 2.3 A proposed mechanism of ABA-HP cleavage to form ABA in the present
of H2O2 based on the reported oxidative cleavage mechanism of boronate ester.23

Monitored by HPLC, we observed that, without H2O2, ABA-HP was not
hydrolyzed to give ABA in HEPES buffer at 37 °C throughout the 24 h observation
period (Figure 2.4). A dimer was observed (based on mass spectrometry analysis,
Figures 2.4 and 2.5) during this incubation period, which was likely formed through the
coordination between the electron deficient boron on ABA-HP with an oxygen lone
pair on another molecule of ABA-HP. Upon the addition of H2O2, ABA-HP started to
convert back to ABA within minutes, and the transformation was completed in 4 h
(Figures 2.4 and 2.5). Following the cleavage process using HPLC, we observed that
besides the regenerated ABA and the dimeric ABA-HP, another peak appeared, which
was converted to ABA at later time points and was likely an intermediate of the
conversion (Figure 2.3).
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Figure 2.4 Time dependent cleavage of ABA-HP by H2O2 detected by HPLC. 1 mM
ABA-HP was treated with 5 mM H2O2 in 50% HEPES/DMSO (10 mM HEPES, pH
7.4) from 0 to 240 min at 37℃. (A) The representative HPLC chromatograms from 3
independent experiments. (B) The quantitative analysis of generated ABA from ABAHP in the presence of H2O2. The results were quantified by integrating the peak area
corresponding to the ABA peak over the total areas of all peaks to give the generated
ABA %. The shown result was the average from 3 independent experiments. Error bars
are SD (N=3).

Figure 2.5 MS of ABA-HP and ABA-HP dimer. TOF-HRMS (m/z) found (calcd.) for
C28H37O6B (M): [M+Na]+, 503.2583 (503.2581) and [2M+Na]+, 983.5185 (983.5264).

To confirm that the dimeric ABA-HP can be converted to ABA, we preincubated
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ABA-HP in HEPES buffer to form the dimer and then treated it with H2O2. We found
that ABA can indeed be generated from this dimer (Figure 2.6).

Figure 2.6 Formation of ABA-HP dimer and its cleavage in the presence of H2O2. 1
mM ABA-HP was incubated in 50% DMSO/HEPES (10 mM HEPES, pH 7.4) for 4 h
(b), and then treated with 5 mM H2O2 for 24 h (c). The chromatograms are
representative results from 3 independent experiments.
Next, we tested the selectivity of ABA-HP toward H2O2 over other ROS, metal
ions, and signaling molecules. ABA-HP was incubated with different molecules as
indicated in Figure 2.7 for 4 h, and the products were analyzed using HPLC. ABA-HP
was found to be unreactive to all molecules tested at 100 μM (Figure 2.7,), except Cu+
and Cu2+, which produced a minimal amount of cleavage but were later shown to have
no effects at the more physiologically relevant concentration of 10 μM (Figure 2.7).
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Figure 2.7 Stability test of ABA-HP upon different molecules detecting by HPLC.
ABA-HP (100 μM) was incubated with 10uM or 100 μM of indicated molecules for 4
h at 37°C. Error bars are SD (N = 3). The results were quantified by integrating the
peak area corresponding to the ABA peak over the total areas of all peaks to give the
generated ABA %. The shown result was the average from 3 independent experiments.
Error bars are SD (N=3).

2.2.2 H2O2 induced transcription activation in living cells

To test if this strategy works in cells, we first investigated whether the H2O2 signal
can be linked to activate transcription since most cell signaling events eventually lead
to gene expression. We used an HEK293T stable cell line, in which enhanced GFP
(EGFP) expression occurs only in the presence of functional ABA.22 This cell line has
both the ABA-responsive split transcriptional activator DNA fragment (VP-PYL and
GAL4DBD-ABI linked by IRES)13 and an inducible EGFP DNA fragment (with
5xUAS) inserted into the genome (Figure 2.8).
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Figure 2.8 DNA constructs for ABA-inducible EGFP expression

To determine if the ABA generated from the H2O2-induced cleavage of ABA-HP
is biologically active, we tested its ability to induce EGFP expression in this HEK293T
reporter cell line. We pre-cleaved ABA-HP with H2O2 and added the resulting products
to the HEK293T cells. After incubation for 7 h, EGFP production was observed under
a fluorescence microscope (Figure 2.9). This result indicates that the regenerated ABA
is indeed biologically active. On the contrary, uncleaved ABA-HP failed to induce
EGFP expression, which confirmed that the boronate modification blocked the activity
of ABA as expected.
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Figure 2.9 EGFP expression in HEK 293T EGFP reporter cells with ABA, ABA-HP
or ABA-HP pre-cleaved by H2O2. Cells were treated with indicated molecules and the
EGFP expression was observed under a fluorescence microscope after 7 h. Images
shown are the representative results from 3 independent experiments.

We next tested whether ABA-HP can respond to H2O2 in cell culture conditions
and cause the gene expression to be activated by H2O2 in cells. It has been reported that
the endogenous H2O2 concentrations of tissue samples vary from 10 to 100 μM range
and that the pathologic tissues usually have even higher levels of H2O2.26-30 We
therefore tested the response of our system to H2O2 at micromolar concentrations in
living cells. The HEK293T reporter cells were treated with no drug, 10 μM ABA, ABAHP, or ABA-HP plus 10, 50, or 100 μM H2O2 for 5 to 24 h. The expression of EGFP
was monitored at indicated time points using a fluorescence microscope. The EGFP
expression was detected only when ABA, or ABA-HP plus H2O2, were added (Figure
2.10). These results confirm that the H2O2-induced cleavage of ABA-HP generates
24

functional ABA in situ. Notably, we observed differential levels of EGFP production
when different amounts of H2O2 were added. The ABA CIP system is known to give a
wide-range of dosage response.13 These results indicate that this dosage response can
be reproduced in the ABA-based H2O2-inducible system. This property can be useful
for converting differential levels of H2O2 signals into different levels of transcription
activity.

Figure 2.10 EGFP expression in HEK293T cells under different treating conditions (10
h). Scale bar is 100 μm.

One concern for the stability of ABA-HP in cells is the existence of an ester linkage
in the molecule, which may be susceptible to the hydrolysis by cellular esterases. In the
above experiments, only a minimal level of the EGFP expression was observed within
a 10 h period following the addition of ABA-HP in the absence of H2O2 (Figure 2.10).
This result suggests that the rate of ABA built up from the esterase cleavage of ABAHP may be much slower than the H2O2-promoted cleavage. We suspect that the bulky
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benzyl boronate moiety may contribute to the enhanced stability when compared to
simple ester structures commonly used in pro-drugs. With an extended incubation
period (24 h), the EGFP expression was indeed observed (Figure 2.11).

Figure 2.11 Dose and time dependent EGFP expression controlled by H2O2 in HEK
293T eGFP reporter cells. Cells were treated with indicated molecules and the EGFP
expression was observed under a fluorescence microscope after indicated times. The
scale bar is 100 μm. Images shown are the representative results from 3 independent
experiments.

When using a more sensitive ABA inducible luciferase reporter assay,16 ABA-HP
26

alone indeed induced observable luciferase expression in a shorter time (within 6 h),
although free ABA induced a much higher expression of luciferase (Figure 2.12). These
results indicate that further structural modifications of the boronate probe (e.g.,
increasing structural bulkiness near the ester linkage)31 will be required to increase the
cellular stability of ABA-HP for applications requiring extended incubation periods.

Figure 2.12 Stability assay of ABA-HP in CHO cells analyzed by the luciferase assay.
CHO cells were transfected with ABA-inducible luciferase reporter constructs. Drugs
were added for 3 or 6 h and then the cells were lysed for luciferase assays. Error bars
are SD (N = 4).

2.2.3 H2O2 induced protein translocation in living cells

Many signaling events are regulated through the dynamic subcellular translocation
of proteins. To test if we can redirect the H2O2 signal to control protein translocation,
we used a reported ABA-inducible EGFP nuclear export system consisting of NES-
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ABI and EGFP-PYL DNA constructs (Figure 2.13).13

Figure 2.13 DNA constructs for ABA-inducible nuclear export of EGFP

CHO cells were transfected with both plasmids for 24 h and then incubated without
additive, or with 10 μM ABA, ABA-HP, or ABA-HP plus 100 μM H2O2 for 30 min.
The subcellular localization of the EGFP-PYL fusion protein was monitored under a
fluorescence microscope, and the percentage of cells showing nuclear export in each
condition was quantified (Figure 2.14). EGFP-PYL showed pan-cellular distribution in
the absence of ABA and was localized outside of the nucleus when ABA was added.
ABA-HP alone did not change the subcellular location of EGFP-PYL. However, the
addition of ABA-HP plus H2O2 caused rapid nuclear export of EGFP-PYL similar to
the case when ABA was added. When different concentrations of H2O2 were added,
dosage-dependent responses were also observed based on the percentage of cells
showing nuclear export (Figure 2.14). The lowest detection limit for H2O2 was observed
to be around 1 μM.
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Figure 2.14 Nuclear export of EGFP in CHO cells under different treating conditions
(30 min). The statistical data was obtained by counting cells to give the percentage of
cells showing nuclear export or ruffling over the total EGFP positive cells. Cells were
counted from three separate experiments each with five different areas chosen randomly,
and over 700 cells were counted for each sample. Scale bar is 20 μm. Error bars are SD
(N = 3).

To characterize and correlate the kinetics of H2O2-promoted ABA-HP cleavage and
H2O2-induced protein translocation, the ABA-HP cleavage and the EGFP-PYL nuclear
export were monitored immediately after ABA-HP and H2O2 addition (from 5 to 30
min, Supplementary Figure 2.15). Followed by HPLC, we observed that ABA was
rapidly generated in 5 min, and the amount was increased with longer incubation
periods. It correlated well with the observation that the EGFP nuclear export occurred
at around 5 min, and the percentage of cells showing EGFP-PYL translocation also
increased with longer incubation periods. These results indicate fast kinetics of ABA
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induced dimerization between PYL and ABI.

Figure 2.15 Time dependent cleavage of ABA-HP in vitro and in cells. (a) 10 μM
ABA-HP was incubated with 100 μM H2O2 in 50% DMSO/HEPES (10mM, pH 7.4) at
37℃ for 5, 10, 20 and 30 min, and then analyzed using HPLC to give the generation
of ABA percentage. The results were quantified by integrating the peak area
corresponding to the ABA peak over the total areas of all peaks to give the generated
ABA %. (b) CHO cells were transfected with NES-ABI & PYL-EGFP plasmids for 24
h. Cells were then treated with no drug, 10 μM ABA, 10 μM ABA-HP or 10 μM ABAHP plus 100 μM H2O2 for 30 min. Cells were counted to obtain the percentage of the
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cells showing unclear export over the total cell number (> 700 cells for each sample).
The shown results were from 3 independent experiments. Error bars are SD (N = 5).

To determine changes at the single cell level, we performed live-cell imaging using
a confocal microscope and quantified the fluorescence intensity inside and outside the
nucleus of a cell at different time points after ABA or ABA-HP plus H2O2 was added
to the transfected cells (Figure 2.16). Consistent with previous observations, cells
started to show decreased fluorescence intensity in the nucleus at around 5 min and
continuing to decrease thereafter. These results demonstrate that we can link the H2O2
signal to the translocation of a protein to a chosen subcellular location. Several
localization signal peptides have been reported,32 which can be used in our system to
transport chosen proteins to different subcellular locations upon the stimulation of H2O2.
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Figure 2.16 Live cell analysis of EGFP nuclear export in CHO cells. Cells were
transfected with NES-ABI & PYL-EGFP plasmids for 24 h and then were treated with
10 μM ABA, 10 μM ABA-HP, or 10 μM ABA-HP plus 100 μM H2O2 and the chosen
cells were followed under a confocal microscope in real time. The fluorescence
intensity was quantified using Slide Book v.6 software as described in methods. The
results were the average of fluorescence intensity ratio of nuclear/cytoplasm from 3
cells in 3 independent experiments.

With this rapidly responsive protein translocation assay at hand, were-evaluated
the stability of ABA-HP against esterases in biological environments (both in cells and
in the serum). CHO cells were transfected with the inducible nuclear export DNA
constructs for 24 h and then incubated either with ABA-HP for 30 min to 4 h or with
ABA-HP that was preincubated (for 30 min to 4 h at 37 °C) with non-heat-inactivated
fetal bovine serum (FBS) for 30 min in cells (Figure 2.17). The nuclear export of EGFPPYL was used as an indication of the ABA-HP hydrolysis. It was found that ABA-HP
was relatively stable in cells within 30 min as only a minimal percentage of cells
showed nuclear export. To rule out the possibility that there may be endogenous H2O2
that could also cleave ABA-HP to give ABA, control experiments were conducted in
which cells were pretreated with catalase, an enzyme that has been used to quench H2O2
in cellular experiments,33 for 1 h before adding ABA-HP. No difference in the
percentages of cells showing nuclear export was observed with or without catalase
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pretreatment. These results suggest that the observed ABA-HP hydrolysis is likely
caused by esterases. To our surprise, ABA-HP that was preincubated with FBS up to 4
h did not lead to obvious nuclear export when incubated in cells for 30 min. If any
cleavage of ABA-HP caused by FBS occurred before adding to cells, a much higher
ratio of cells showing nuclear export would be expected. This observation suggests that
ABA-HP is stable in FBS for at least 4 h. The difference in results between the
incubation in cells and in FBS may likely be due to the different level of esterases in
each condition.

Figure 2.17 Stability of ABA-HP in cells and in FBS. CHO cells were transfected with
NES-ABI & PYL-EGFP plasmids for 24 h before the drugs. Cells were treated with (a)
no drug; (b) ABA for 0.5, 1, 1.5, 2 and 4 h; (c) ABA-HP for 0.5, 1, 1.5, 2 and 4 h; (d)
FBS pre-incubated ABA-HP (at 37 ℃ for 0.5, 1, 1.5, 2 and 4 h) for 30 min; (e) 1
mg/mL of catalase for 1 h and then ABA-HP for 0.5, 1, 1.5, 2 and 4 h. The results were
33

analyzed by counting the cells showing EGFP unclear export over the total cell number
(> 700 cells for each sample). The shown results were from 3 independent experiments.
Error bars are SD (N = 5).

2.2.4 H2O2 induced cytoskeletal remodeling in living cells

To further investigate whether we can integrate the de novo H2O2 signal
components into an endogenous signaling network, we examined the possibility of
routing the H2O2 signal to induce membrane ruffling through the activation of the
endogenous Rac1 signaling pathway. Tiam1 is a guanine exchange factor for Rac1,
which is a member of Rho GTPase. The membrane translocation of Tiam1 activates
Rac1 signaling and induces ruffle formation.34 We constructed an ABA-inducible
Tiam1 membrane localization system, which consists of DNA plasmids encoding the
membrane-localized ABI (myr-ABI)13 and the cytoplasmic EGFP/PYL-fused Tiam1
(PYL-EGFP-Tiam1) (Figure 2.18).

Figure 2.18 DNA constructs for ABA-inducible Rac1 signaling/ruffle formation.

CHO cells were transfected with these plasmids for 24 h and then incubated for 30
min without additive, or with 10 μM ABA, ABA-HP, or ABA-HP plus 100 μM
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H2O2.The ruffle formation was analyzed by counting the number of cells showing
morphological changes among all EGFP positive cells using a confocal microscope. As
expected, only when cells were treated with ABA, or ABA-HP plus H2O2, did they
show increased ruffle formation (Figure 2.19). Either ABA-HP or H2O2 alone gave
background levels of ruffling similar to those without drug addition. These results
indicate that the ruffling was caused by the presence of free ABA instead of by H2O2
alone.

Figure 2.19 Ruffle formation of CHO cells under different treating conditions (30 min).
The statistical data was obtained by counting cells to give the percentage of cells
showing nuclear export or ruffling over the total EGFP positive cells. Cells were
counted from three separate experiments each with five different areas chosen randomly,
and over 700 cells were counted for each sample. Scale bar is 20 μm. Error bars are SD
(N = 3). *P-value < 0.001.

To further confirm that the observed ruffling was induced through activating the
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endogenous Rac1 signaling, the transfected cells were treated with a Rac1 inhibitor,
NSC23766 (50 μM), for 1 h before adding ABA or ABA-HP plus H2O2. NSC 23766 is
known to block the binding between Tiam1 and Rac1 and inhibit the activation of Rac1
signaling.35 The NSC 23766 treatment lead to decreases in the percentage of cells
showing ruffling in both cases of ABA and ABA-HP plus H2O2 addition (Figure 2.19),
which indicated that the Tiam1-activated Rac1 signaling was indeed involved in the
observed H2O2-induced ruffling. To examine whether the degree of ruffling can be
reduced to the background level, we used higher concentrations of NSC 23766, which,
however, led to severe cell death. Alternatively, when we treated cells with lower
concentrations of ABA-HP (5 μM) and H2O2 (50 μM), the ruffling was indeed reduced
to the background level with the NSC 23766 (50 μM) treatment (Figure 2.20). Overall,
the above results demonstrate that our approach enabled an endogenous signaling
pathway to become responsive to a new signal (i.e., H2O2), which is not normally
associated with the pathway in the tested cell type.
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Figure 2.20 Ruffle formation of CHO cells in 30 min. The statistical data were obtained
by counting the cells to give the percentage of the cells with ruffling over the total cell
number. Cells were counted from three separate experiments with 5 different areas by
random and > 700 cells for each sample. Error bars are SD (N=3). *P-value < 0.001.

2.2.5 Response to endogenous H2O2 in living cells

We next tested whether the created H2O2 signaling system can respond to
endogenously generated H2O2 instead of exogenously applied H2O2 as in previous
experiments. It has been reported that A431 cells can be stimulated by epidermal growth
factor (EGF) to produce H2O2 in micromolar concentrations.36-37 A431 cells were
transfected with the inducible EGFP nuclear export DNA constructs for 24 h and then
treated with no drug, ABA-HP alone, 10 μM ABA-HP plus 100 μM H2O2, or 10 μM
ABA-HP plus 500 or 1000 ng/mL of EGF. The percentage of cells showing EGFP-PYL
nuclear export in each condition was then quantified using a fluorescence microscope.
The EGFP nuclear export was readily detected within 30 min after EGF stimulation,
which was similar to the case when cells were stimulated by exogenous H2O2 (Figure
2.21). No obvious EGFP nuclear export was observed without EGF stimulation. To
confirm that H2O2 was indeed generated by the EGF stimulation to give the observed
EGFP-PYL translocation, the EGF stimulated cells were treated with catalase for 1 h
before adding ABA-HP. The level of EGFP nuclear export was found to reduce to a
level similar to the case when cells were treated with ABA-HP only (without H2O2 or
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EGF) (Figure 2.21). These results clearly demonstrate that the engineered H2O2
signaling system can respond to the H2O2 generated endogenously in cells.

Figure 2.21 Nuclear export of EGFP in A431 cells under different treating conditions.
The statistical data was obtained by counting cells to give the percentage of cells
showing nuclear export or ruffling over the total EGFP positive cells. Cells were
counted from three separate experiments each with five different areas chosen randomly,
and over 700 cells were counted for each sample. Scale bar is 20 μm. Error bars are SD
(N = 3). *P-value < 0.001.

2.3 Design and application of GA-HP

We expect that the same strategy can be expanded to other CIP inducers, which will
allow us to build orthogonal signaling pathways in the same cell and potentially to
construct cross talking pathways. To test this possibility, we applied this strategy to the
GA-based CIP system. GA induces the binding between GAI and GID1 proteins in a
similar way as ABA does.38 GA has been developed as an orthogonal CIP system that
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was used to perform cellular computing.14 GA is not cell permeable. It was modified as
the acetoxy methoxy ester (GA-AM) to cross the cell membrane and subsequently be
cleaved by esterases to generate functional GA.14 It has been shown that the carboxylate
group on GA is critical for its biological functions. A minor modification that converts
the carboxylate into a nonhydrolyzable hydroxamate abolishes its CIP activity.14

2.3.1 Synthesis and HPLC test of GA-HP

A recent report also showed that photolabile groups can be linked to the carboxylate
group on GA to cage its activity.39 We expect that modifying this carboxylate group of
GA with the H2O2-sensitive boronate probe will give an H2O2-responsive GA system.
We synthesized GA-HP by coupling the boronate group to GA (Figures 2.22 and 2.23).

Figure 2.22 Synthesis of GA-HP and its conversion to GA in the presence of H2O2.
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Figure 2.23 A proposed mechanism of GA-HP cleavage to form GA in the present of
H2O2 based on the reported oxidative cleavage mechanism of boronate ester.

We analyzed the chemical stability of GA-HP and its conversion back to GA upon
H2O2 addition using HPLC. In the presence of H2O2, GA was rapidly regenerated from
GA-HP within 2 h (Figures 2.24 and 2.25).
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Figure 2.24 Time dependent cleavage of GA-HP by H2O2 detected by HPLC. 5 mM
GA-HP was treated with 50 mM H2O2 in 50% HEPES/DMSO (10 mM HEPES, pH 7.4)
from 0 to 120 min at 37℃. The HPLC chromatograms shown are representative from
3 independent experiments.

Figure 2.25 GA-HP (5 mM) was treated with or without 50 mM of H2O2 for indicated
time periods. The results shown are representative from 3 independent experiments.
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It was observed that, without H2O2, GA-HP did not release GA when incubated in
HEPES buffer for 24 h, although the boronate group was partially hydrolyzed as
reported in a similar case to give an inert but convertible product (Figures 2.26).40

Figure 2.26 MS of partial hydrolyzed GA-HP. TOF-HRMS (m/z) found (calcd.) for
C26H29O8B (M): [M+Na]+, 503.1857 (503.1853).

We also tested the selectivity of GA-HP against different ROS and cellular metals
and found that GA-HP was selective for H2O2 among tested molecules (Figures 2.27
and 2.28).
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Figure 2.27 Reaction selectivity of GA-HP (1 mM) against H2S and different ROS (1
mM) in 50% DMSO/HEPES at 37℃ for 4 h. The results were analyzed by HPLC. H2S
was generated by Na2S in HEPES buffer (pH 7.4). •OH and •OtBu were generated by
reaction of Fe2+ with H2O2 or tert-butyl hydroperoxide (TBHP), respectively. The
HPLC chromatograms shown are representative from 3 independent experiments.
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Figure 2.28 Reaction selectivity of GA-HP (1 mM) against common cellular metal ions
(1 mM) in 50% HEPES/DMSO. The results were analyzed by HPLC after 4-h
incubation in 37 ℃ . Shown HPLC chromatograms are representative from 3
independent experiments.

2.3.2 H2O2 induced protein translocation in living cells based on GA-CIP system

To examine if we can produce biologically active GA from GAHP in the presence
of H2O2 in cells, we made DNA constructs to encode a nuclear exported GID1 (NESGID1) and a pan-cellular distributed EGFP-tagged GAI (EGFP-GAI) (Figure 2.29).

Figure 2.29 DNA constructs for GA-inducible EGFP nuclear export

CHO cells were transfected with these plasmids for 24 h and then incubated without
additive or with 100 μM GA-AM, GA-HP, or GA-HP plus 100 μM H2O2 for 30 min.
The percentage of cells showing EGFP-GAI nuclear export was quantified in each
condition using a fluorescence microscope (Figure 2.30). Only cells treated with GAAM or GA-HP plus H2O2 showed nuclear export, which indicated that functional GA
was generated from GA-HP upon H2O2 addition. Given that GA cannot cross the cell
membrane, the observed intracellular effects suggested that the H2O2-induced cleavage
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of GA-HP occurred inside the cells. The successful implementation of this strategy
using GA demonstrates the potential generality of our strategy.

Figure 2.30 Nuclear export of EGFP in CHO cells under different treating conditions
(30 min). CHO cells were transfected with these plasmids in Figure 2.29, and then
treated with different conditions. The statistical data was obtained by counting cells to
give the percentage of cells showing nuclear export over the total EGFP positive cells.
Cells were counted from three separate experiments each with five different areas
chosen randomly, and over 700 cells were counted for each sample. Scale bar is 20 μm.
Error bars are SD (N = 3). *P-value < 0.001.

2.4 Conclusion

In conclusion, we have developed a novel strategy integrating CIP methods and
H2O2-sensing to construct de novo cell signaling pathways that redirected H2O2 to
control different cellular processes (i.e., transcription and protein translocation) or to
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interface with an existing endogenous signaling circuit (i.e., the Rac1 signaling). We
have showed that ABA can be converted to become responsive to exogenous or
endogenous H2O2 stimulation rapidly and specifically at physiologically relevant
concentrations. Moreover, this strategy can be generally applied to different CIP
inducers (i.e., ABA and GA). It provides the potential to expand this strategy in building
signaling networks when each orthogonal CIP inducer is designed to become activated
by a unique signal. We expect that sensing units for different cell signals can be used to
replace the H2O2 sensing unit used in this study to switch the responding specificity.4142

We believe that our novel strategy to engineer de novo cell signaling circuits will

have wide applications in the fields of cell signaling research, biocomputing, and
synthetic biology and contribute to the future development of gene and cell therapies
for human diseases.

2.5 Methods

2.5.1 Chemical synthesis

General. 1H (300 MHz) and 13C (75 MHz) NMR were recorded on a Bruker Avance
500. All commercially available reagents were used without further purification. The
progress on the reactions was monitored by analytical thin-layer chromatography (TLC)
on Whatman silica gel plates with UV indicator. And Merk 60 silica gel was used for
chromatography.
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Figure 2.31 Synthesis of ABA-HP and GA-HP

Synthesis of 2-[4-(Bromomethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
(2). To 4-(bromomethyl)phenylboronic acid (200 mg, 0.93 mmol, Sigma Aldrich ) in 1
mL toluene was added pinacol (165 mg, 1.40 mmol, Sigma Aldrich), then heated to
reflux with Dean-Stark trap and stirred for 3 h. The solvent was removed by rotavapor,
and the product was purified through column chromatography (EA : Hex = 1:3) and
obtained as white solid (250 mg, 91%). Also compound 2 was synthesized through
compound 1. 1H-NMR (300 MHz, CDCl3), δ (ppm): 1.340 (12H, s), 4.488 (2H, s),
7.378-7.404 (2H, d, J = 7.8Hz), 7.772-7.798 (2H, d, J = 7.8Hz).

Synthesis of ABA-HP (3). To ABA (44 mg, 0.17 mmol, Gold Biotechnology, USA)
in 10 mL CH3CN was added compound 2 (55 mg, 0.19 mmol) and DBU (55 µL, 0.37
mmol, Sigma Aldrich), then stirred at RT for 4 h. The solvent was removed by rotavapor,
then the product was purified by column chromatography (EA : Hex = 1:3) to give
white solid (50 mg, 62%). The compound was characterized by 1H and 13C NMR and
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high-resolution mass spectrometry with > 95% purity based 1H NMR. HPLC was used
for further purification before biological activity test. 1H-NMR (300 MHz, CDCl3), δ
(ppm): 0.997 (3H, s), 1.097 (3H, s), 1.334 (12H, s), 1.896 (3H, s), 2.004 (3H, s), 2.165
(1H, s), 2.254-2.311 (1H, d, J = 17.1Hz), 2.443-2.500 (1H, d, J = 17.1Hz), 5.155 (2H,
s), 5.802 (1H, s), 5.917 (1H, s), 6.130-6.183 (1H, d, J = 15.9Hz), 7.345-7.372 (2H, d, J
= 8.1Hz), 7.785-7.812 (2H, d, J = 8.1Hz), 7.855-7.910 (1H, d, J = 16.5Hz). 13C-NMR
(75 MHz, CDCl3), δ (ppm): 18.9, 21.3, 23.1, 24.3, 24.8, 41.5, 49.8, 65.7, 79.6, 83.8,
118.3, 127.0, 127.2, 128.1, 135.0, 136.5, 139.1, 149.7, 162.4, 165.6, 197.7. TOF-HRMS
(m/z) found (calcd.) for C28H37O6B (M): [M+Na]+, 503.2583 (503.2581) and
[2M+Na]+, 983.5185 (983.5264).

Synthesis of GA-HP (4).
CH3CN

was

added

To GA (100 mg, 0.29 mmol, Alfa Aesar) in 20 mL

compound

2

(102.9

mg,

0.35

mmol)

and

1,8-

Diazabicyclo[5.4.0]undec-7-ene (DBU, 52 µL, 0.35 mmol, Sigma Aldrich), then stirred
at RT for 4 h. The solvent was removed by rotavapor, and the product was purified by
column chromatography (EA : Hex = 1:1) and obtained as white solid (97 mg, 60%).
The compound was characterized by 1H and

13

C NMR and high-resolution mass

spectrometry with > 95% purity based 1H NMR. HPLC was used for further purification
before biological activity test. 1H-NMR (300 MHz, CDCl3), δ (ppm): 1.198 (3H, s),
1.338 (12H, s), 1.632-2.172 (9H, m), 2.795-2.831 (1H, d, J = 10.8Hz), 3.200-3.236 (1H,
d, J = 10.8Hz), 4.127 (1H, s), 4.876 (1H, s), 5.117-5.231 (3H, m), 5.867-5.910 (1H, dd,
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J = 3.6, 9.3Hz), 6.280-6.313 (1H, d, J = 9.9Hz), 7.318-7.345 (2H, d, J = 8.1Hz), 7.7787.805 (2H, d, J = 8.1Hz). 13C-NMR (75 MHz, CDCl3), δ (ppm): 14.8, 17.3, 25.1, 38.4,
43.1, 45.1, 50.8, 51.0, 51.4, 53.1, 53.7, 67.1, 69.9, 75.4, 78.3, 84.2, 90.8, 107.8, 127.7,
132.7,133.0, 135.3, 138.5, 157.0, 172.3, 179.0. TOF-HRMS (m/z) found (calcd.) for
C32H39O8B (M): [M+Na]+ , 585.2653 (585.2636).

2.5.2 Reverse-phase HPLC analysis

Chemical stability and reactivity of ABA-HP towards H2O2. ABA-HP chemical
stability: 1 mM ABA-HP (in DMSO) was incubated in 50% HEPES/DMSO (10 mM
HEPES, pH 7.4) for 24 h at 37 ℃. HPLC results were detected at 0 min, 20 min, 40
min, 60 min, 80 min, 100 min, 120 min, 240 min, and 24 hrs. ABA-HP reactivity
towards H2O2: 1 mM ABA-HP was incubated with 5 mM (5 eq) H2O2 in 50%
HEPES/DMSO (10 mM HEPES, pH 7.4) at 37 ℃ . The cleavage products were
detected at 0, 20, 40, 80, 100, 120 and 240 min by HPLC. 100 mM H2O2 was diluted
with 11 μL of 30% (10 M) stock H2O2 (VWR) and 989 μL of ddH2O. All concentrations
shown were the final concentration. HPLC chromatograms were acquired using
Dionex-UltiMate 3000 LC System with Acclaim 120 Å, C18, 3 µm analytical (4.6 x
100 mm) column. Chromatographic conditions: eluent A: 0.1% v/v TFA in water; eluent
B: 0.1% v/v TFA in acetonitrile. ABA in ethanol or ABA-HP in DMSO was eluted at a
flow rate of 0.750 ml/min monitored at a wavelength of 260 nm. 0-12 min (linear): 95%
A, 5% B to 5% A, 95% B; 12-15 min: 5% A, 95% B; 15-17 min (linear): 5% A, 95% B
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to 95% A, 5% B. Generation of ABA was quantified by the peak area of ABA out of
the total peak area.

Reaction selectivity versus different molecules. 100 μM ABA-HP was incubated
with 100 μM (1 eq) of different molecules as indicated in 50% HEPES/DMSO (pH 7.4)
at 37℃ for 4 h and the cleavage products were detected by HPLC. H2S was generated
by 100 μM Na2S solution in HEPES buffer, which can slowly release H2S. •OH and
•OtBu were generated by reaction of Fe2+ with H2O2 or tert-butyl hydroperoxide
(TBHP), respectively. HPLC condition was the same as the stability and reactivity test
of ABA-HP.

Chemical stability and reactivity of GA-HP towards H2O2. GA-HP chemical
stability: 5 mM GA-HP (in DMSO) was incubated in 50% HEPES/DMSO (10 mM
HEPES, pH 7.4) for 24 h at 37 ℃ and the products were analyzed by HPLC. GA-HP
reactivity towards H2O2: 5 mM GA-HP was incubated with 50 mM (10 eq) H2O2 in 50%
HEPES/DMSO (10 mM HEPES, pH 7.4) at 37 ℃. The products were analyzed at 5,
30, 60, 90 and 120 min using HPLC. HPLC chromatograms were acquired using
Dionex-UltiMate 3000 LC System with Acclaim 120 Å, C18, 3 µm analytical (4.6 x
100 mm) column. Chromatographic conditions: eluent A: 0.1% v/v TFA in water; eluent
B: 0.1% v/v TFA in acetonitrile. Solutions in DMSO were eluted at a flow rate of 1.000
ml/min monitored at a wavelength of 206 nm. 0-12 min (linear): 95% A, 5% B to 5%
A, 95% B; 12-16 min: 5% A, 95% B; 16-18 min (linear): 5% A, 95% B to 95% A, 5%
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B.

2.5.3 Cloning and plasmid construction

All DNA fragments were amplified by PCR (Polymerase chain reaction) from other
intermediate constructs with the enzyme of Phusion DNA Polymerase (New England
Biolabs), or PfuUltra II Fusion HotStart DNA Polymerase (Agilent Technologies) under
S1000 thermal cycler with Dual 48/48 Fast Reaction Module (Bio-Rad). All the
restriction enzymes used below are purchased from New England Biolabs. PYL-EGFPTiam1 construct was derived from pSV40-VP16-PYL-IRES-Gal4DBD-ABI12 by
inserting codon optimized PYL fragment

(PCR

amplified by primers CCGACA

GAATTCGCCACCAT-GACCCAGGACGAGTTTACCCAG

and

CCGACAGGC

GCGCCGCTGCCGCCGTTCATAGCCTCAGTAATGCT) using EcoRI and AscI sites,
Tiam1-SG linker fragment

(amplified by primers GCTATGAACGGCGCGCCA

AGTGCTGGTGGTAGTGCTGGT and CTAGAGTCGCGGCCGCTCAGATCTCA
GTGTTCAGTTTC) using AscI and NotI sites, and eGFP-SG-linker fragment
(amplified by primers CCGACAGGCGCGCCAGGTGGATCTGGAGGTTCAGG
TGGATCTGGAGGTGTGAGCAAGGGCGAGGAGCTG and CCGACAGGCGCG
CCCTTGTACAGCTCGTCCATGCC) using

AscI

site. NES-GID1 construct was

generated from NES-ABI25 by inserting GID1 fragment (amplified by
CCGACAACGCGTGGATCTGGTGGAGCTGCGAGCGATGAGTTAAT

primers
and

CCGACAGCGGCCGCTCAACATTCCGCGTTTACAAACGC) using MluI and NotI
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sites. EGFP-GAI construct was generated from eGFP-PYL.12 GAI fragment (amplified
by

primers

CCGACAGGCGCGCCAGGATCTGGTGGAAAGAGAGATCATC-

ATCATCAT and CCGACAGGATCCTCAAGGATTAAGGTCGGTGAGCAT) was
inserted by AscI and blunt end ligation into AscI and blunted NotI sites on the vector.

2.5.4 Mammalian cell culture and transfection

All cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS,
2 mM GlutaMAX (life technologies), 100 U/ml penicillin (life technologies) and 100
μg/ml streptomycin (life technologies) at 37℃ in a humidified atmosphere containing
5% CO2.

EGFP expression experiments. HEK 293T EGFP reporter cells were seeded 24 h
prior to treatment in 24-well plates at 100,000/well. 10 μM ABA-HP was added to the
cells 10 min prior to the addition of 10 μM ABA and 10, 50, or 100 μM of H2O2. Images
were taken for living cells at 5, 7, 10 and 24 h.

NES localization experiments in CHO cells. CHO cells were seeded over glass
coverslips in 24-well plates at 50,000/well for 24 h. 0.4 μg NES-ABI and 0.2 μg EGFPPYL DNA plasmids were mixed with 30 μL of Opti-MEM (life technologies) and 1.8
μL of PEI (Polysciences). After incubation at RT for 15 min, the mixture was added to
the cells and cultured for 24 h. Then, 10 μM ABA or 10 μM ABA-HP plus 100 μM of
H2O2 (ABA-HP added 10 min prior to H2O2), or 100 μM GA or 100 μM GA-HP plus
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100 μM of H2O2 (GA-HP added 10 min prior to H2O2) was added to the cells. 30 min
after adding compounds, the coverslips were washed with phosphate-buffered saline
(PBS) and fixed with 300 μL of 4% paraformaldehyde (PFA, prepared in PBS) at room
temperature for 20 min. The cells were then washed twice with PBS and incubated with
1x DAPI in the dark at the room temperature for 5 min.

After a final wash with PBS,

the coverslips were mounted on a glass slide with Vectashield (VWR) mounting media
and images of cells were then taken using a fluorescence microscope.

Live cells imaging experiment for CHO cells with nuclear export experiments and
its analysis. CHO cells were seeded in 8 Chamber coverglass plate at 25,000/well for
24 h. 0.2 μg NES-ABI and 0.1 μg EGFP-PYL DNA plasmids were mixed with 15 μL
of Opti-MEM (life technologies) and 0.9 μL of PEI (Polysciences). After incubation at
RT for 15 min, the mixture was added to the cells and cultured for 24 h. Medium was
changed 1 h before the addition of 10 μM ABA, 10 μM ABA-HP with and without 100
μM H2O2. Images were taken every 30 secs for duration of 20 min for the same area.
Images generated were analyzed for fluorescent intensity using Slide Book v.6 software.
Equal sized regions of interest were analyzed to get the EGFP fluorescent intensity ratio
of the nucleus over cytoplasm. Three cells for each condition were analyzed to get the
average ratio and normalized.

NES localization experiments in A431 cells. A431 cells were seeded over glass
coverslips in 24-well plates at 100,000/well for 24 h. 0.4 μg NES-ABI and 0.2 μg
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EGFP-PYL DNA plasmids were mixed with 30 μL of Opti-MEM and 1.8 μL of PEI.
After incubation at RT for 15 min, the mixture was added to the cells and cultured for
24 h. Then, 10 μM ABA or 10 μM ABA-HP plus 100 μM of H2O2 or plus 500 ng/mL
hEGF (Sigma-Aldrich) (ABA-HP added 10 min prior to H2O2 or hEGF) was added to
the cells. Slides were prepared 30 min after adding compounds and images were then
taken using a fluorescence microscope.

NES localization experiments in A431 and CHO cells treated with catalase. Cells
were seeded over glass coverslips in 24-well plates at 100,000/well for A431 cells and
50,000/well for CHO cells 24 h before the transfections. 0.4 μg NES-ABI and 0.2 μg
EGFP-PYL DNA plasmids were mixed with 30 μL of Opti-MEM and 1.8 μL of PEI.
After incubation at RT for 15 min, the mixture was added to the cells and cultured for
24 h. Then, cells were treated with 1mg/mL of catalase (Sigma-Aldrich, C1345) by
changing the medium with catalase for 1 h incubation, followed by the addition of other
drugs.

Ruffle generation experiment. CHO were seeded over glass coverslips in 24-well
plates at 50,000/well for 24 h. 0.1 μg PYL-EGFP-Tiam1 and 0.1 μg myr-ABI DNA
plasmids were mixed with 30 μL of Opti-MEM and 1.8 μL PEI. After incubation at
room temperature for 15 min, the mixture was added to the cells and cultured for 24 h.
Then, 10 μM ABA or 10 μM ABA-HP plus 100 μM of H2O2 (ABA-HP added 10 min
prior to H2O2) (or 5 μM ABA or 5 μM ABA-HP plus 50 μM of H2O2) was added to the
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cells. For the cells treated with rac1 inhibitor NSC 23766, 50μM of NSC 23766 was
added to the medium 1h prior to drug addition. Slides were prepared 30 min after adding
compounds and images were then taken using a Zeiss LSM 510 META Confocal
Microscopy the next day.

Luciferase reporter assay with CHO cells. CHO were seeded over glass coverslips
in 24-well plates at 50,000/well for 24 h. 0.1 μg 5 × FL and 0.5 μg SV-VP-PYL-iresGal-ABI DNA plasmids were mixed with 30 μL of Opti-MEM and 1.8 μL PEI. After
incubation at RT for 15 min, the mixture was added to the cells and cultured for 24 h.
10 μM ABA-HP or ABA was added to the cells. After 6 h, cells were washed with PBS
and lysed with 100 μL of Reporter Lysis Buffer (Promega) by incubating and gently
shaken at room temperature for 10 min. Cell lysates were centrifuged at 15,000 rpm in
an Eppendorf Centrifuge 5424 and 10 μL of lysate was used for luciferase assay. 100
μL of luciferase assay reagent (5 mg luciferin (GoldBio) and 7 mg coenzyme A (Sigma)
in

33

mL

of

Luciferase

Assay

Buffer

[20

mM

tricine,

1.07

mM

(MgCO3)4Mg(OH)2•5H2O, 2.67 mM MgSO4, 0.1 mM EDTA, 33.3 mM dithiothreitol,
and 0.53 mM ATP in water) was added to lysates. Luciferase assay reagent was added
through the auto-injector of GLOMAX-Multi Detection System (Promega), and the
signal was detected by the instrument with a 1.5 s delay and 0.5 s integration time.

All

experiments were conducted in triplicate.

Fluorescence microscopy. Zeiss Axio Observer. D1 outfitted with HBO 100
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microscopy illumination system (GFP: excitation 470/40 and emission 525/50) and
Zeiss LSM 510 META Confocal Microscopy outfitted with GFP/Alexa Fluor 488 (491
laser excitation, 528/38 emission) were used. EGFP expression experiment: Zeiss Axio
Observer. D1 was used with the 20× objective and image areas were chosen randomly.
NES localization: Zeiss Axio Observer. D1 was used with the 63× oil-immersion
objective. Ruffle formation: Zeiss LSM 510 META Confocal Microscopy with 40× and
63× oil-immersion objectives. Fluorescent channels in all experiments were adjusted to
the same intensity ranges. Acquisition times ranged from 100 to 1000 ms.

Statistical Analysis of Cell Population. Cell were categorized as displaying nuclear
export of EGFP when the fluorescent intensity of the nucleus was less than 60% of the
intensity over the cytoplasm.

Cells were categorized as Ruffled when they displayed

broad extensions identifiable as lemellopodia or fillopodia from the GFP fluorescence
from membrane localized EGFP-PYL-Tiam1. Cells were counted from three separate
experiments with 5 different areas by random and > 700 cells for each sample. P values
were obtained by using EXCEL with the function “CHISQ.TEST”.
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Chapter 3
Engineering Iron Responses in Mammalian Cells by Signal-Induced
Protein Proximity
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3.1 Introduction

The aim of synthetic biology research is to rewire biological systems in order to
understand and control the functions of cellular systems that ultimately lead to novel
therapies.1-6 Cell signaling translates extracellular signals into intracellular processes
that carry out cellular functions. The introduction of artificial signaling networks using
synthetic biology methods has facilitated the investigation of signaling mechanisms and
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the identification of essential components in signaling pathways. 7-10 Several synthetic
biology methods that are based on chemical controls have been developed to provide
precise temporal regulation.1, 11 We recently reported a new strategy to engineer custom
signaling pathways in mammalian cells that integrates the chemically induced
proximity (CIP) technology

12-13

14

and reactivity-based signal sensing. The approach

enables cells to link H2O2 or light with different cellular responses including gene
activation, protein translocation, and cytoskeleton remodeling.15-16 The method uses
caged CIP inducers (e.g., abscisic acid (ABA)17) that are inactive until being stimulated
by a specific signal (e.g., H2O2) that removes the caging group and activates an inducer
to promote the heterodimerization of selected PYL/ABI fusion proteins. Induced
protein dimerization then triggers predesigned biological outputs. Our continuing
investigations in this are aimed at testing the generality of this strategy for creating new
signaling pathways for other important stimuli and exploring the possibility of
constructing cross-talking pathways. In the study described below, we have developed
a method to engineer artificial Fe2+ signaling that responds to elevated Fe2+ levels and
to build “AND” and “OR” Boolean logic-based signaling circuitries that respond to a
combination of H2O2 and Fe2+ in a predefined manner.

Iron is the most abundant transition metal in humans and its redox chemistry
interconverting Fe2+ and Fe3+ plays numerous biological roles.18 Although most iron
ions exist in complexes with proteins, free Fe2+ is present in cellular environments
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where it is believed to participate in critical physiological functions.19 An increased
level of Fe2+ has been observed in brains of patients with neurodegenerative diseases
(e.g., Alzheimer’s disease (AD) and Parkinson’s diseases (PD)).20 It is proposed that the
combination of elevated levels of Fe2+ and H2O2 (under oxidative stress) leads to the
production of free radicals which promote neuron death in AD and PD.

21-23

The

availability of an engineered system that enables cells to detect elevated levels of H2O2
and Fe2+ in local environments and respond with specific therapeutic outputs would
contribute to the development of novel therapies for AD and PD.

3.2 Design, synthesis and screening of ABA-FEs

Several fluorescent probes have been developed to assess the level of Fe2+ in living
cells.

24-28

Included in this group is the new reactivity-based “off-on” fluorescent reporter

we recently developed, which is based on unique Fe2+-mediated cleavage of N-aryl-Oacylhydroxyalamine.29 We envisioned that the chemistry involved in the Fe2+ sensing
of this probe could be employed to design novel Fe2+ responsive ABA inducers that
specifically control Fe2+-induced cellular effects through ABA mediated protein
dimerization (Figure 3.1).
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Figure 3.1 General process for Fe2+-induced proximity to control biological processes.

3.2.1 Synthesis of ABA-FEs

Because free Fe2+ also exists in a normal cellular environment, caged inducers of
this type must be stable under normal cellular Fe2+ concentrations and only become
activated at abnormally high Fe2+ concentrations. To this end, we designed and
synthesized a library of ABA derivatives (ABA-FE1 to 26) that contain differently
substituted aniline, benzyl amine, and oxime derivatives conjugated to the carboxylate
group of ABA through an O−N linkage (Figures 3.2-3.5). The aniline, benzylamine,
and oxime moieties in these substances contain a variety of electron donating and
withdrawing groups to enable tuning of the reactivity of the O−N linkage against Fe2+.
Bulky substituents (e.g., phenyl or tbutyl groups) were also introduced at the benzylic
position of the benzyl amine and oxime groups to adjust the lability of the ester linkage
caused by cellular esterases.
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Figure 3.2 Synthesis of ABA-FE1-8.
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Figure 3.5 Structures of ABA-FEs

3.2.2 Screening of ABA-FEs

3.2.2.1 Screening of ABA-FEs with HPLC

To identify ABA-FEs that undergo Fe2+ specific bond cleavage and that are stable
under cellular conditions (i.e., tolerating normal cellular levels of Fe2+ and other
biomolecules), we probed the reactivity and selectivity of ABA-FEs using a series of
assays. To check their chemical stability, ABA-FEs were incubated in the HEPES
buffer at 37 °C for 1 h followed by HPLC analysis. The percentage of ABA generated
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from each ABA-FE (indicating cleavage efficiency) was quantified. In the series, ABAFE2 and ABA-FE8 are not stable under these conditions (Figure 3.6) and therefore
eliminated from further studies.

Figure 3.6 Stability of ABA-FEs. (A) Stability of ABA-FEs in HEPES/DMSO. 10 µM
ABA-FE was incubated in 50% HEPES/DMSO (10 mM HEPES, pH 7.4) for 1 h at
37°C, followed by HPLC analysis. The results were quantified by integrating the peak
area corresponding to the ABA peak over the total areas of ABA peak and caged ABA
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peak to give the generated ABA percentage. The shown results were the average from
3 independent experiments. Error bars are SD (N=3). (B) Representative HPLC
chromatograms of the analysis. Peak A is ABA, peak C is ABA-FE18, and peak B is
the released byproduct. ABA% = area A/(area A + area C) x 100%.

To examine their relative Fe2+ promoted reactivity, 10 μM of ABA-FEs was
incubated with 10 and 100 eq of Fe2+ for 1 h followed by HPLC analysis (Figure 3.7).
Theresults show that ABA-FE5 and ABA-FE25 are not reactive even with the high
level of Fe2+. Many ABA-FEs displayed high reactivity in the presence of the lower
level of Fe2+. However, ABA-FE16 to 21, and ABA-FE26 have much lower reactivity
at the low Fe2+ concentrations but reactive at high Fe2+ level. Most ABA-FEs have low
reactivity toward Fe3+ (Figure 3.8).

Figure 3.7 ABA-FEs (10 μM) treated with 10 eq and 100 eq Fe2+, respectively, for 1 h
and then quantified using HPLC analysis.
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Figure 3.8 Reactivity of ABA-FEs towards Fe3+. 10 µM ABA-FE was incubated with
100 µM Fe3+ in 50% HEPES/DMSO (10 mM HEPES, pH 7.4) for 1h at 37°C, followed
by the HPLC analysis. The results were quantified by integrating the peak area
corresponding to the ABA peak over the total areas of ABA peak and caged ABA peak
to give the generated ABA percentage. The shown results were the average from 3
independent experiments. Error bars are SD (N=3).

Since ABA-FE18 gave the most desired reactivity profile, we further tested its
reactivity against various cellular molecules including metal ions (e.g., Cu2+, Zn2+,
Mg2+, Ca2+, Na+) and oxidizing or reducing species (e.g., H2O2, Na2S, cysteine,
ascorbate). The results show that ABA-FE18 is selective and undergoes cleavage
reaction to give ABA only in the presence of high concentrations of Fe2+ but not in the
presence of the other tested molecules and ions (Figure 3.9).
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Figure 3.9 Stability test of ABA-FE18 detecting with HPLC. ABA-FE18 treated with
indicated ions and molecules (10 eq for all unlabeled items) for 1 h and then quantified
using HPLC analysis. The results were quantified by integrating the peak area
corresponding to the ABA peak over the total areas of ABA peak and caged ABA peak
to give the generated ABA percentage. The shown results were the average from 3
independent experiments. Error bars are SD (N=3). Error bars are SD (N = 3).

To further characterize ABA-FE18, the time course of ABA-FE18 cleavage was
tested by incubating it with 100 eq of Fe2+ for 5 min to 24 h. The cleavage of ABAFE18 occurred rapidly and was near completion at 1 h (Figure 3.10). In addition, the
dosage response of ABA-FE18 versus different concentrations of Fe2+ (1 to 500 equiv)
was also studied. It required 100 eq or higher level of Fe2+ to achieve significant ABAFE18 cleavage, although less than 50 eq also gave low to moderate level of cleavage
(Figure 3.11).
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Figure 3.10 Time course of ABA-FE18 cleavage by 100 eq of Fe2+. 10 µM ABA-FE18
was incubated with 100 eq of Fe2+ in 50% HEPES/DMSO (10mM HEPES, pH 7.4) for
5 min, 30 min, 1 h, 2 h, 4 h, 8 h and 24 h at 37˚C, followed by HPLC analysis. The
results were quantified by integrating the peak area corresponding to the ABA peak
over the total areas of ABA peak and caged ABA peak to give the generated ABA
percentage. The shown results were the average from 3 independent experiments. Error
bars are SD (N=3).
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Figure 3.11 Dosage response of ABA-FE18 versus different concentrations of Fe2+. 10
µM ABA-FE18 was incubated with 1 eq, 5 eq, 10 eq, 25 eq, 50 eq, 100 eq and 500 eq
of Fe2+ in 50% HEPES/DMSO (10 mM HEPES, pH 7.4) for 1 h at 37˚C, followed by
HPLC analysis. The results were quantified by integrating the peak area corresponding
to the ABA peak over the total areas of ABA peak and caged ABA peak to give the
generated ABA percentage. The shown results were the average from 3 independent
experiments. Error bars are SD (N=3).

3.2.2.2 Screening of ABA-FEs in living cells

To determine the cellular stability and reactivity of ABA-FEs toward Fe2+ in cells,
a HEK293T reporter cell line was used. This cell line contains ABA-response gene
cassettes stably integrated in the genome that encode a split transcriptional activator
(VP-PYL/GAL4DBD-ABI) and an inducible enhanced green fluorescent protein
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(EGFP) with 5xUAS upstream (Figure 3.12).15

Figure 3.12 DNA constructs for ABA-inducible EGFP expression.

As a result, it produces EGFP in the presence of ABA. The cellular stability of
ABA-FE18 and other ABA-FEs was tested by incubating them (20 μM) with the
reporter cells for 10 h. ABA and no drug treatment were used as positive and negative
controls. The level of EGFP production, which indicates the degree of ABA-FE
cleavage, was then determined using a fluorescence plate reader (Figure 3.13). Because
the Fe2+ sensing units in ABA-FEs are linked to ABA through ester linkages, the
endogenous cellular esterases can potentially affect the stability of ABA-FEs in cells.
We expected that ABA-FEs containing bulky substituents close to the ester linkage (i.e.,
ABA-FE14−26) should have higher stability against esterases. Indeed, we observed
several compounds in this group including ABA-FE18 induced lower levels of EGFP
expression (Figure 3.13). ABA-EF22−24 induced a much higher level of EGFP
expression, which may be due to their higher sensitivity toward low levels of Fe2+
(Figure 3.7) or other molecules in cells.
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Figure 3.13 Cellular stability of ABA-FEs. 20 µM of ABA-FE (or with and without
ABA as positive and negative controls) was incubated in the HEK293T EGFP reporter
cell line for 10 h followed by the quantification of EGFP production using a
fluorescence plate reader. The shown results were the average from 4 independent
experiments. Error bars are SD (N = 4).

Considering its cellular stability, Fe2+-responsive characteristics and selectivity for
Fe2+, ABA-FE18 was subjected to further characterization. We incubated ABA-FE18
with EGFP reporter cells for longer time periods (up to 24 h) and observed that it is
relatively stable (Figure 3.14), although some low levels of EGFP expression had been
observed that indicates further optimization will be needed for applications requiring
long incubation times. To ensure the lack of EGFP expression in the above assay was
due to the superior stability of ABA-FE18 in cells instead of the complete degradation
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of the compound, we also added 100 eq of Fe2+ in a separate experiment under the
similar condition and showed that EGFP expression can be induced (Figure 3.14),
which demonstrated that ABA-FE18 was still functional to respond to Fe2+ and to
generate ABA. We did not observe obvious cytotoxicity that can potentially be caused
by the released Fe2+-sensing unit.

Figure 3.14 Cellular stability and reactivity of ABA-FE18 over extended times.
HEK293T EGFP reporter cells were treated with 20 µM ABA, ABA-FE18, or ABAFE18 plus 100 eq of Fe2+ for 18 and 24 h. (A) The production of EGFP was quantified
using a fluorescence plate reader. The showed results were the average from 4
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independent experiments. Error bars are SD (N = 4). (B) The representative image for
each experimental condition.

To rule out the possibility that the uncaged byproduct of ABA-FE18 can induce
observed effects, we synthesized the Fe2+-sensing unit released from ABA-FE18 after
cleavage and incubated it with EGFP reporter cells. We observed no EGFP expression
was induced or obvious toxicity to cells (Figure 3.15).
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Figure 3.15 Testing effects of the uncaged byproduct from ABA-FE18. HEK293T
EGFP reporter cells were treated with 20 µM ABA, ABA-FE18 or the uncaged
byproduct with or without 100 eq of Fe2+ for 24 h. (A) The production of EGFP was
quantified using a fluorescence plate reader. The showed results were the average from
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4 independent experiments. Error bars are SD (N = 4). (B) Representative images for
each experimental condition.

3.3 Fe2+ induced biological processes in living cells

3.3.1 Fe2+ induced transcription activation in different living cells

The stability of ABA-FE18 and its ability to connect Fe2+ to gene activation in
mammalian cells were explored. For this purpose, HEK293T EGFP reporter cells, or
cells (including HeLa, B35, and CHO cells) transfected with ABA-inducible EGFP
reporter plasmids (Figure 3.12), were treated with 20 μM of ABA-FE18 in the presence
or absence of 100 eq of Fe2+ for 10 h. The induced EGFP expression was quantified in
each condition using fluorescence plate reader and flow cytometer (Figure 3.16-3.18).
ABA-FE18 was found to be reasonably stable in all tested cell lines and it readily
induced EGFP expression in response to the added high level of Fe2+. On the basis of
the combined observations described above, ABA-FE18 was identified as the optimal
ABA-FE-based Fe2+- responding inducer.
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Figure 3.16 Induced EGFP expression by ABA or Fe2+ in different cell lines using
micro plate reader. The fold changes are calculated based on “no drug” treatment
samples.

Figure 3.17 Induced EGFP expression by ABA or Fe2+ in different cell lines using flow
cytometry. HEK293T EGFP reporter cells, and transfected CHO, HeLa and B35 cells
were treated with 20 µM ABA, ABA-FE18, or ABA-FE18 plus 100 eq of Fe2+. After
10 h, cells were collected and analyzed by flow cytometry for EGFP expression. 10,000
cells were analyzed for each condition. Mean fluorescence intensity from analyzed cells
under each condition was obtained and normalized to that of the non-treated cells. Error
bars are SD (N = 3).
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Figure 3.18 Representative images for each condition in Figure 3.16 and 3.17.

3.3.2 Fe2+ induced cytoskeletal remodeling in different living cells

In addition to directing an external Fe2+ signal to induce transcriptional activation,
we wanted to explore whether artificial Fe2+ signaling can be constructed and integrated
into an endogenous signaling circuit. For this purpose, we determined if Fe2+-promoted
release of ABA from ABA-FE can be used to induce cytoskeletal remodeling via
activation of the Rac1 signaling pathway. Membrane translocation of Tiam1, a guanine
exchange factor for Rac1, is sufficient to activate the Rac1 signaling pathway that leads
to membrane ruffling.30 CHO cells were transfected with DNA constructs (Figure 3.19)
encoding membrane-localized ABI (myr-ABI) and cytoplasmic EGFP-PYL-fused
Tiam1 (PYL-EGFP-Tiam1)15 for 24 h. The cells were then treated either with 10 μM of
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ABA, ABA-FE18, or ABA-FE18 plus 100 eq of Fe2+ for 30 min. The membrane
ruffling in all EGFP positive cells was then quantified through statistical analysis that
quantified individual cell perimeters in each treated condition and compared them to
that from cells transfected with EGFP-PYL (see Methods for details of analysis) using
images taken by the fluorescence microscope. Obvious increases in ruffle formation
were found to occur only when cells were treated with ABA or ABA-FE18 plus 100 eq
of Fe2+ (Figures 3.19 and 3.20).

Figure 3.19 DNA constructs for ABA-inducible Rac1 signaling/ruffle formation
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Figure 3.20 Ruffle formation of CHO cells. The ratio was calculated as described in
the Methods section. Error bars are SD (SD = 4). *P value < 0.001

ABA-FE18 alone gave a similar background level of ruffling as the condition of
no-drug treatment or cells transfected only with PYL-EGFP-Tiam1 (Figures 3.20 and
3.21). To confirm that ruffle formation is induced through activation of Rac1 signaling,
transfected cells were pretreated for 1 h with 50 μM of NSC 23766, which is known to
inhibit Rac1 signaling by blocking binding of Tiam1 to Rac1.31 As expected, the
presence of NSC 23766 led to a decrease in the percentage of ruffling in cells treated
with ABA and ABA-FE18 plus Fe2+ (Figure 3.20).

Figure 3.21 The ratio of cells showing ruffling in cells in negative and positive control
conditions. CHO were seeded over glass coverslips in 24-well plates at 50,000/well for
24 h. Then cells were transfected with 0.3 µg EGFP-PYL only, or 0.3 µg PYL-EGFP-
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Tiam1 only or 0.3 µg PYL-EGFP-Tiam1 and 0.3 µg myr-ABI DNA. After 24 h, cells
were treated without addition, or with 10 µM ABA. Slides were prepared 30 min after
adding ABA and images were then taken using a Zeiss fluorescence microscopy for
statistical analysis.

3.4 Constructing of “AND” or “OR” Boolean logic to control the nuclear
translocation of EGFP

To demonstrate that orthogonal signal-responsive caged CIP inducers can be
incorporated to build artificial signaling networks, ABA-FE18 and GA-HP15 were used
to construct two signaling networks that process different combinations of H2O2 and
Fe2+ via “AND” or “OR” Boolean logic to control the nuclear translocation of EGFP.
GA-HP is a H2O2-responsive caged compound containing gibberellic acid (GA),15
which promotes the dimerization of GAI and GID1 fusion proteins.32

3.4.1 Constructing of “OR” Boolean logic to control the nuclear translocation of
EGFP

To create an OR logic gate for protein translocation, DNA constructs encoding
4xNLS-ABI-GID1 and PYL-GAI-GFP fusion proteins (Figure 3.22) were made. In the
presence of either ABA or GA, the EGFP fusion protein should be coupled to the
nuclear localization signal (NLS) and lead to nuclear localization of EGFP (Figure 3.23).
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Figure 3.22 DNA constructs of OR logic gate for EGFP nuclear translocation.

Figure 3.23 The design of the OR logical gate for EGFP nuclear translocation in
response to stimuli.

To validate the OR logic gate, CHO cells were transfected with both plasmids for
24 h and then treated for 30 min with 20 μM ABA, 100 μM GA-AM (acetoxymethoxy
ester of GA to facilitate cell permeability),32 or both ABA and GA-AM. Nuclear
localization of EGFP was then quantified through statistical analysis using images taken
by the fluorescence microscope (Figure 3.24). The results show that, as designed, either
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ABA or GA is sufficient to induce the EGFP translocation. To test if this logic gate
system can be used to allow cells to respond to H2O2 and Fe2+, the experiments were
repeated using ABA-FE18 and GAHP in the presence or absence of 100 μM H2O2
and/or 100 eq Fe2+. As expected, the transfected cells responded to either or both H2O2
and Fe2+ to induce the translocation of EGFP. The cleavage of ABA-FE18 by Fe2+ can
occur both outside and inside the cells, and the generated ABA can freely diffuse across
the cell membrane to induce effects. However, the observed effects induced by H2O2
should result from the cleavage of GA-HP in cells because free GA cannot pass the cell
membrane.32

Figure 3.24 Ratio of transfected CHO cells (with plasmids in panel A) showing EGFP
nuclear localization after treating with different inducing signals for 1 h. Error bars are
SD (N = 4). *P-value < 0.001.
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3.4.2 Constructing of “AND” Boolean logic to control the nuclear translocation of
EGFP

To demonstrate that a different processing algorithm in response to detected signals
can be engineered, we also created an AND logic gate for EGFP nuclear translocation
using constructs encoding 4xNLS-GID1, GAI-ABI, and EGFP-PYL (Figures 3.25 and
3.26).

Figure 3.25 DNA constructs of AND logic gate for EGFP nuclear translocation.

Figure 3.26 The design of the AND logical gate for EGFP nuclear translocation in
response to stimuli.

Nuclear localization of EGFP was observed to take place in transfected CHO cells
only when they were treated with both ABA and GA-AM (Figure 3.27). Similarly,
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nuclear localization of EGFP in transfected cells that are treated with ABA-FE18 and
GA-HP occurred only when both Fe2+ and H2O2 were present. These observations
demonstrate that the cells can be reprogrammed to respond to Fe2+ and/or H2O2 and
produce different biological outputs following predefined signal processing rules.

Figure 3.27 Percentage of transfected CHO cells (with plasmids in (A)) showing EGFP
nuclear localization after being treated with different inducing signals for 1 h. Error
bars are SD (N = 4). *P-value < 0.001.

3.5 Conclusion

In conclusion, in the investigation described above, we have developed Fe2+responsive ABA derivatives and identified ABA-FE18 as an optimal Fe2+-responsive
inducer. We discovered that in general the oxime-based sensor units increased the
stability of ABA-FEs against Fe2+ (e.g., ABA-FE19−21 vs 22−24) and electron90

withdrawing substituents decreased the reactivity toward Fe2+ within this group (e.g.,
ABA-FE17, 20, 21). We also demonstrated that adding bulky substituents near ester
linkage can increase its stability in cells. Particularly, we identified oxime as a new,
stable, and Fe2+ specific linkage (e.g., ABA-FE18). We believe that these observations
can provide useful information for further optimization and future design of similar
molecules. Our works present a unique strategy that specific sensor units can be
integrated into orthogonal CIP inducers to build custom signaling pathways and logic
gates responding to physiologically relevant signal cues. This new strategy should
provide alternative approaches to engineer cellular signaling and responses in
mammalian cells.

3.6 Materials and Methods

3.6.1 Primers

5’ GAI ATG SalI

CCGACAGTCGACGCCACCATGAAGAGAGATCATCATCATCAT

3’ GAI GS linker MluI

CCGACAACGCGTACCTGATCCACCTCCACCAGATCCAGGATTAAGGTCGGT
GAGCA
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5’ ABI MluI

CCGACAACGCGTGTGCCTTTGTATGGTTTTACT

3’ ABI MluI

CCGACAACGCGTCTTATCGTCATCGTCCTTGTA

5’ GAI GSGGGGSG AscI

CCGACAGGCGCGCCAGGATCTGGTGGAGGTGGATCAGGTAAGAGAGATCA
TCATCATCAT

3’ GAI GGSGGGAGGGGSGGGAGG AscI

CCGACAGGCGCGCCACCGCCAGCGCCTCCTCCGCTACCACCCCCTCCTGCC
CCCCCGCCGGATCCTCCAGGATTAAGGTCGGTGAGCAT

3.6.2 Chemical synthesis

General Information: All reactions were carried out in dried flasks. The reactions
were monitored by TLC for completion. Commercially available reagents were used as
received without further purification unless otherwise specified. Merck 60 silica gel
was used for column chromatography, and Whatman silica gel plates with fluorescence
F254 were used for thin-layer chromatography (TLC) analysis. 1H and

13

C NMR

spectra were recorded on Bruker Avance 300. Data for 1H NMR are reported as follows:
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chemical shift (ppm), and multiplicity (s = singlet, d = doublet, t = triplet, q = quartet,
dd = double doublet, ddd = double double doublet, td = triple doublet, dt = double triplet,
m = multiplet, bs = broad signal). Data for 13C NMR are reported as ppm.

3.6.2.1 Synthesis of ABA-FE1-8

Substrates 1b-8b were prepared according to literature procedure. To an ice cold
solution of substitute nitrobenzenes 1a-8a (8.00 mmol) in 95% ethanol (50 mL) was
added zinc powder (12.0 mmol). Acetic acid (24 mmol) was then added dropwise and
the reaction stirred for 2 h. The reaction was filtered to remove the zinc, avoiding over
reduction to the amine. The ethanol was removed under reduced pressure, and the crude
material was dissolved in methylene chloride, and directly absorbed onto silica gel by
reduced pressure removal of the solvent. Flash column chromatography (ethyl acetate
in hexanes as eluent) produced pure product.

Preparation of ABA-FE1-8: Compound 1b-8b (0.01 mmol), EDCI (0.022 g, 0.12
mmol), ABA (0.026 g, 0.01 mmol) were suspended in DCM (15 mL) and stirred at
room temperature for 18 h. The mixture was washed with H2O and brine, dried over
Na2SO4, and concentrated in vacuo. The residue was subjected to silica gel
chromatography to afford the compounds ABA-FE1-8.

3.6.2.2 Synthesis of ABA-FE9-15, 22-26
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The synthesis of the target compounds ABA-FE9-15, 22-26 was accomplished in
a convergent manner as shown in Schemes 1. Commercially available substituted
acetophenones 9a-15a, 22a-26a were the starting materials for the synthesis of ABAFE9-15, 22-26, respectively. Compounds 9a-15a, 22a-26a were each treated with
hydroxylamine hydrochloride to give the corresponding oxime intermediates 9b-15b,
22b-26b, which was then reduced by NaBH3CN to afford 9c-15c, 22c-26c with
hydroxylamine group. Finally, these hydroxylamines 9c-15c, 22c-26c coupled with
ABA to afford the target compounds ABA-FE9-15, 22-26.
Substrates 9b-15b, 22b-26b were prepared according to literature procedure.33 A
solution of phenome 9a-15a, 22a-26a (0.90 mmol), sodium acetate (0.90mol) and
hydroxylamine hydrochloride (5.4 mmol) in hydrous ethanol (20 mL) was refluxed for
4-24 h at 80oC. The reaction mixture was allowed to cool to room temperature and
evaporated to dryness in vacuo, and the residue was partitioned between water (10 mL)
and CH2Cl2 (10 mL). The organic extract was washed with water (2-10 mL), and the
aqueous layer was extracted with CH2Cl2 (2-10 mL). The combined organic extracts
dried over anhydrous sodium sulfate and evaporated in vacuo gave the corresponding
oximes 9b-15b, 22b-26b (85-97%).
Substrates 9c-15c, 22c-26c were prepared according to literature procedure.34 A
solution of 9b-15b, 22b-26b (200 μmol, 1.0 equiv) in MeOH (10 mL) was treated with
NaBH3CN (13.7 mg, 200 μmol, 1.0 equiv) and methyl orange (< 1 mg). The reaction
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mixture was then kept at pH 3–4 by dropwise addition of aqueous HCl (1 N). After 2 h
the reaction was basified to pH 10 (1 N NaOH), solid NaCl was added and the resulting
mixture was extracted thrice with CH2Cl2 (20 mL). The combined organic layers were
dried over Na2SO4 and concentrated to give a cude oil, which was purified by flash
chromatography (hexanes/EtOAc 1:1) to give 9c-15c, 22c-26c (70-89%) as a colorless
solid.

Preparation of ABA-FE9-15, 22-26: Compound 9c-15c, 22c-26c (0.01 mmol),
EDCI (0.022 g, 0.12 mmol), ABA (0.026 g, 0.01 mmol) were suspended in DCM (15
mL) and stirred at room temperature for 18 h. The mixture was washed with H2O and
brine, dried over Na2SO4, and concentrated in vacuo. The residue was subjected to silica
gel chromatography to afford the compounds ABA-FE9-15, 22-26.

3.6.2.3 Synthesis of ABA-FE16-21

Preparation of ABA-FE16-21: Compound 16b-21b (0.01 mmol), EDCI (0.022 g,
0.12 mmol), ABA (0.026 g, 0.01 mmol) were suspended in DCM (15 mL) and stirred
at room temperature for 4 h. The mixture was washed with H2O and brine, dried over
Na2SO4, and concentrated in vacuo. The residue was subjected to silica gel
chromatography to afford the compounds ABA-FE16-21.

3.6.2.4 NMR and mass data of ABA-FE1-26
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(S)-4-hydroxy-3,5,5-trimethyl-4-((1E,3Z)-3-methyl-5-(3-nitrophenylaminooxy)5-oxopenta-1,3-dienyl) cyclohex-2-enone (ABA-FE1)

The title compound was obtained in 68% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm): 8.97 (s, 1H), 7.75-7.81 (m, 2H), 7.35-7.41 (m, 1H), 7.20-7.14
(m, 1H), 6.18 (d, J = 16.5 Hz, 1H), 5.84-5.87 (m, 2H), 2.23-2.45 (m, 2H), 2.05 (s, 3H),
1.97 (s, 1H), 1.83(s, 3H), 1.03(s, 3H), 0.94(s, 3H). TOF-HRMS (m/z) found (calcd.) for
C21H24N2O6 (M): [M+H]+, 401.1715 (401.1713); [M+Na]+, 423.1511 (423.1532) and
[M+K]+, 439.1275 (439.1271).

(S)-4-hydroxy-3,5,5-trimethyl-4-((1E,3Z)-3-methyl-5-(2-nitrophenylaminooxy)-5oxopenta-1,3-dienyl)cyclohex-2-enone (ABA-FE2)

The title compound was obtained in 71% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm): 10.92 (s, 1H), 7.92(d, J = 15.9 Hz, 1H), 7.73 (dd, J = 1.2 Hz,
8.4 Hz, 1H), 7.55-7.60 (m, 1H), 7.30-7.33 (m, 1H), 7.01-7.06(m, 1H), 6.26 (d, J = 15.6
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Hz, 1H), 5.93 (s, 2H), 2.27-2.50 (m, 2H), 2.08 (s, 3H), 2.04 (s, 1H), 1.90(s, 3H), 1.10(s,
3H), 1.00(s, 3H). TOF-HRMS (m/z) found (calcd.) for C21H24N2O6 (M): [M+H]+,
401.1532 (401.1713); [M+Na]+, 423.1537 (423.1532).

4-((2Z,4E)-5-((S)-1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-enyl)-3-methylpenta2,4-dienoyloxyamino)benzonitrile (ABA-FE3)

The title compound was obtained in 65% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm): 8.97 (s, 1H), 7.91(d, J = 15.9 Hz, 1H), 7.58 (d, J = 8.7 Hz, 2H), 7.05
(d, J = 8.7 Hz, 2H), 6.23 (d, J = 15.9 Hz, 1H), 5.87-5.94 (m, 2H), 2.26-2.49 (m, 3H),
2.10 (s, 3H), 1.89 (s, 3H), 1.10 (s, 3H), 1.01 (s, 3H). TOF-HRMS (m/z) found (calcd.)
for C22H24N2O4 (M): [M+H]+, 381.1826 (381.1814); [M+Na]+, 403.1645 (403.1634)
and [M+K]+, 419.1390 (419.1373).

(S)-4-((1E,3Z)-5-(4-acetylphenylaminooxy)-3-methyl-5-oxopenta-1,3-dienyl)-4hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE4)

97

The title compound was obtained in 66% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm): 8.99 (s, 1H), 7.80-7.91(m, 3H), 7.03 (d, J = 8.7 Hz, 2H), 7.05 (d, J =
8.7 Hz, 2H), 6.22 (d, J = 15.9 Hz, 1H), 5.88-5.93 (m, 2H), 2.54 (s, 3H), 2.26-2.49 (m,
2H), 2.09 (s, 3H), 2.03 (s, 1H), 1.89 (s, 3H), 1.09 (s, 3H), 1.00 (s, 3H). TOF-HRMS
(m/z) found (calcd.) for C23H27NO5 (M): [M+H]+, 398.1973 (398.1967); [M+Na]+,
420.1778 (420.1787) and [M+K]+, 436.1521 (436.1526).

(S)-4-hydroxy-4-((1E,3Z)-5-(2-iodophenylaminooxy)-3-methyl-5-oxopenta-1,3dienyl)-3,5,5-trimethylcyclohex-2-enone (ABA-FE5)

The title compound was obtained in 71% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm): 8.88 (s, 1H), 8.22 (dd, J = 1.2 Hz, 8.4 Hz, 1H), 7.86(d, J = 16.2 Hz,
1H), 7.26-7.32 (m, 1H), 7.06-7.09 (m, 1H), 6.74-6.79(m, 1H), 6.27 (d, J = 15.6 Hz, 1H),
5.88-5.93 (m, 2H), 2.33-2.45 (m, 2H), 2.08 (s, 3H), 2.03 (s, 1H), 1.90(s, 3H), 1.10(s,
3H), 1.00(s, 3H). TOF-HRMS (m/z) found (calcd.) for C22H27NO4 (M): [M+H]+,
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370.2010 (370.2018); [M+Na]+, 392.1830 (392.1838) and [M+K]+, 408.1577
(408.1577).

(S)-4-((1E,3Z)-5-(((2-chlorophenyl)amino)oxy)-3-methyl-5-oxopenta-1,3-dien-1-yl)4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE6)

OH
O

O

O

H
N

Cl

The title compound was obtained in 63% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm): 9.08 (s, 1H), 7.86-7.92 (m, 1H), 7.47-7.50 (m, 1H), 7.24-7.29
(m, 1H), 7.12-7.16(m, 1H), 6.88-6.93(m, 1H), 6.22 (d, J = 16.0 Hz, 1H), 5.93 (s, 1H),
5.88 (s, 1H), 2.27-2.50 (m, 2H), 2.08 (s, 3H), 2.04 (s, 1H), 1.90(s, 3H), 1.10(s, 3H),
1.00(s, 3H). TOF-HRMS (m/z) found (calcd.) for C21H24ClNO4 (M): [M+H]+,
390.1474 (390.172) and [M+K]+, 428.1028 (428.1031).

(S)-4-((1E,3Z)-5-(((2-bromophenyl)amino)oxy)-3-methyl-5-oxopenta-1,3-dien-1-yl)4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE7)
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The title compound was obtained in 63% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm): 9.08 (s, 1H), 7.86-7.92 (m, 1H), 7.47-7.50 (m, 1H), 7.24-7.29
(m, 1H), 7.12-7.16(m, 1H), 6.88-6.93(m, 1H), 6.22 (d, J = 16.0 Hz, 1H), 5.93 (s, 1H),
5.88 (s, 1H), 2.27-2.50 (m, 2H), 2.08 (s, 3H), 2.04 (s, 1H), 1.90(s, 3H), 1.10(s, 3H),
1.00(s, 3H). TOF-HRMS (m/z) found (calcd.) for C21H24BrNO4 (M): [M+H]+,
434.0977 (434.0967); [M+Na]+, 456.0790 (456.0786) and [M+K]+, 472.0541
(472.0526).

(S)-4-hydroxy-3,5,5-trimethyl-4-((1E,3Z)-3-methyl-5-oxo-5-(o-tolylaminooxy) penta1,3-dienyl) cyclohex-2-enone (ABA-FE8)

The title compound was obtained in 72% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm): 7.98(d, J = 15.9 Hz, 1H), 6.54-6.96 (m, 4H), 6.22 (d, J = 15.9 Hz, 1H),
5.90(s, 1H), 6.04 (s, 1H), 2.20-2.50(m, 4H), 2.03-2.12 (m, 5H), 1.89 (s, 3H), 1.10 (s,
3H), 1.00 (s, 3H). TOF-HRMS (m/z) found (calcd.) for C21H24INO4 (M): [M+H]+,
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482.0817 (482.0828); [M+Na]+, 504.0635 (504.0648) and [M+K]+, 520.0383
(520.0387).

(4S)-4-hydroxy-3,5,5-trimethyl-4-((1E,3Z)-3-methyl-5-oxo-5-(1phenylethylaminooxy) penta-1,3-dienyl) cyclohex-2-enone (ABA-FE9)

The title compound was obtained in 83% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.76-7.81 (m, 1H), 7.71 (s, 1H), 7.28-7.39 (m, 5H), 6.18 (d, J = 16.0
Hz, 1H), 5.93 (s, 1H), 5.67 (s, 1H), 4.13 (t, J = 7.2 Hz, 1H), 2.26-2.49 (m, 2H), 2.13 (s,
1H), 2.03(s, 3H), 1.90(s, 3H), 1.43(d, J = 6.0 Hz, 3H), 1.28(s, 3H), 1.23(s, 3H). TOFHRMS (m/z) found (calcd.) for C23H29NO4 (M): [M+H]+, 384.2160 (384.2175);
[M+Na]+, 406.1985 (406.1994) and [M+K]+, 422.1725 (422.1734).

(4S)-4-((1E,3Z)-5-(1-(4-bromophenyl)ethylaminooxy)-3-methyl-5-oxopenta-1,3dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE10)
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The title compound was obtained in 76% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm): 7.78-7.83 (m, 1H), 7.70 (s, 1H), 7.46-7.49 (m, 2H), 7.26-7.28
(m, 2H), 6.15 (d, J = 16.0 Hz, 1H), 5.95 (s, 1H), 5.66 (s, 1H), 4.14 (t, J = 7.2 Hz, 1H),
2.27-2.51 (m, 2H), 2.05 (s, 1H), 1.99(s, 3H), 1.91(t, J = 1.2 Hz, 3H), 1.43(d, J = 6.0 Hz,
3H), 1.12(s, 3H), 1.10(s, 3H).

13

C NMR (75.5 MHz, CDCl3) δ (ppm): 197.4, 165.9,

161.9, 150.6, 140.5, 136.9, 131.4, 128.5, 127.7, 126.9, 121.3, 115.0, 79.4, 59.9, 49.5,
41.3, 24.1, 22.8, 21.0, 19.6, 18.7. TOF-HRMS (m/z) found (calcd.) for C23H28BrNO4
(M): [M+H]+, 462.1288 (462.1280); [M+Na]+, 484.1101 (484.1099) and [M+K]+,
500.0842 (500.0839).

(4S)-4-hydroxy-4-((1E,3Z)-5-(((1-(4-methoxyphenyl)ethyl)amino)oxy)-3-methyl-5oxopenta-1,3-dien-1-yl)-3,5,5-trimethylcyclohex-2-enone (ABA-FE11)

The title compound was obtained in 73% yield as white solid. 1H NMR (300 MHz,
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CDCl3) δ (ppm): 7.79 (m, 1H), 7.70 (s, 1H), 7.27-7.29 (m, 2H), 6.88-6.92 (m, 2H), 6.15
(d, J = 16.0 Hz, 1H), 5.94 (s, 1H), 5.65 (s, 1H), 4.12 (d, J = 6.6 Hz, 1H), 2.27-2.51 (m,
2H), 2.03 (s, 1H), 1.99(s, 3H), 1.90(t, J = 1.2 Hz, 3H), 1.43(s, 3H), 1.12(s, 3H), 1.10(s,
3H). TOF-HRMS (m/z) found (calcd.) for C24H31NO5 (M): [M+H]+, 414.2278
(414.2280); [M+Na]+, 436.2097 (436.2100) and [M+K]+, 452.1848 (452.1839).

(4S)-4-((1E,3Z)-5-(((1-(2-chlorophenyl)ethyl)amino)oxy)-3-methyl-5-oxopenta-1,3dien-1-yl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE12)

OH
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The title compound was obtained in 78% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm): 7.82 (s, 1H), 7.78 (s, 1H), 7.60-7.63 (m, 1H), 7.28-7.36 (m, 3H),
7.17-7.23(m, 1H), 6.13 (d, J = 16.0 Hz, 1H), 5.93 (s, 1H), 5.65 (s, 1H), 4.63 (s, 1H),
2.26-2.49 (m, 2H), 1.98(d, J = 1.2 Hz, 3H), 1.90(d, J = 1.2 Hz, 3H), 1.43(d, J = 6.0 Hz,
3H), 1.10(s, 3H), 0.99(s, 3H). TOF-HRMS (m/z) found (calcd.) for C23H28ClNO4 (M):
[M+H]+, 418.1781 (418.1785); [M+Na]+, 440.1593 (440.1605) and [M+K]+, 456.1325
(456.1344).
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(4S)-4-hydroxy-3,5,5-trimethyl-4-((1E,3Z)-3-methyl-5-(1-(naphthalen-1yl)ethylaminooxy)-5-oxopenta-1,3-dienyl)cyclohex-2-enone (ABA-FE13)

The title compound was obtained in 76% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.77-7.87 (m, 6H), 7.47-7.56 (m, 3H), 6.18 (d, J = 16.2 Hz, 1H), 5.94
(s, 1H), 5.67 (s, 1H), 4.38 (s, 1H), 2.27-2.50 (m, 2H), 2.06 (s, 1H), 1.98 (s, 3H), 1.881.90 (m, 6H), 1.53 (d, J = 6.6 Hz, 3H), 1.10 (s, 3H), 0.99 (d, J = 6.6 Hz, 3H). 13C NMR
(75.5 MHz, CDCl3) δ (ppm): 197.4, 166.0, 162.0, 150.3, 138.9, 138.8, 136.7, 133.1,
132.8, 128.1, 127.7, 127.5, 126.9, 115.3, 79.4, 60.6, 53.2, 49.5, 41.3, 24.1, 22.8, 21.0,
19.9, 18.7. TOF-HRMS (m/z) found (calcd.) for C27H31NO4 (M): [M+H]+, 434.2333
(434.2331); [M+Na]+, 456.2156 (456.2151) and [M+K]+, 472.1885 (472.1890).

(4S)-4-hydroxy-3,5,5-trimethyl-4-((1E,3Z)-3-methyl-5-oxo-5-(1phenylbutylaminooxy)penta-1,3-dienyl)cyclohex-2-enone (ABA-FE14)
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The title compound was obtained in 65% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.79 (s, 1H), 7.74 (s, 1H), 7.26-7.33 (m, 7H), 6.17 (d, J = 16.2 Hz, 1H),
5.92 (s, 1H), 5.63 (s, 1H), 3.96 (m, 1H), 2.25-2.48 (m, 2H), 2.03 (s, 1H), 1.97(s, 3H),
1.89(t, J = 1.2 Hz, 3H), 1.19-1.29(m, 4H), 1.09(s, 3H), 0.98(s, 3H), 0.85-0.90( m, 3H).
13

C NMR (75.5 MHz, CDCl3) δ (ppm): 197.6, 166.0, 162.2, 150.2, 140.4, 136.8, 128.2,

127.7, 127.5, 127.3, 126.8, 115.3, 79.4, 66.8, 66.5, 49.5, 41.3, 35.8, 35.3, 24.1, 22.9,
21.0, 19.6, 18.7, 13.8. TOF-HRMS (m/z) found (calcd.) for C25H33NO4 (M): [M+H]+,
412.2494 (412.2488); [M+Na]+, 434.2316 (434.2307) and [M+K]+, 450.2051
(450.2047).

(4S)-4-((1E,3Z)-5-(((1,2-diphenylethyl)amino)oxy)-3-methyl-5-oxopenta-1,3dien-1-yl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone. (ABA-FE15)

The title compound was obtained in 81% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.74-7.79 (m, 2H), 7.21-7.32 (m, 8H), 7.10-7.12(m, 2H), 6.13 (d, J =
16.2 Hz, 1H), 5.94 (s, 1H), 5.64 (s, 1H), 4.30 (s, 1H), 3.04-3.15(m, 2H), 2.28-2.50 (m,
2H), 2.06 (s, 1H), 1.98(s, 3H), 1.90(s, 3H), 1.11(s, 3H), 1.03(s, 3H). TOF-HRMS (m/z)
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found (calcd.) for C26H35NO4 (M): [M+H]+, 426.2649 (426.2644); [M+Na]+,
448.2466(448.2464) and [M+K]+, 464.2211(464.2203). TOF-HRMS (m/z) found
(calcd.) for C29H33NO4 (M): [M+H]+, 460.2490 (460.2488); [M+Na]+, 482.2320
(482.2307) and [M+K]+, 498.2050 (498.2047).

(4S)-4-((1E,3Z)-5-((phenyl)(phenyl)methylaminooxy)-3-methyl-5-oxopenta1,3-dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE16)

OH
O
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N

The title compound was obtained in 77% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.91-7.97 (m, 1H), 7.29-7.61 (m, 10H), 6.17 (d, J = 15.9 Hz, 1H), 5.93
(s, 1H), 5.62-5.66 (m, 1H), 5.21 (s, 1H), 3.04-3.15(m, 2H), 2.25-2.49 (m, 2H), 2.04 (s,
1H), 1.89-2.04 (m, 6H), 0.85-1.10(m, 6H).

(4S)-4-((1E,3Z)-5-((2-chlorophenyl)(phenyl)methylaminooxy)-3-methyl-5oxopenta-1,3-dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE17)
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The title compound was obtained in 82% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm) 7.91-7.97 (m, 1H), 7.28-7.65 (m, 9H), 6.27 (dd, J = 16.8 Hz, 8.1
Hz, 1H), 5.95 (s, 1H), 5.58-5.79 (m, 1H), 2.27-2.52 (m, 2H), 1.93-2.07 (m, 7H), 1.03
(s, 3H), 0.85 (s, 3H). 13C NMR (75.5 MHz, CDCl3) δ (ppm): 197.6, 163.6, 163.5, 162.4,
157.9, 151.4, 137.0, 133.5, 131.4, 131.0, 129.3, 128.7, 127.9, 127.6, 126.8, 120.4, 115.6,
111.5, 79.3, 49.6, 41.3, 24.1, 22.8, 21.1, 18.7.

(4S)-4-((1E,3Z)-5-((2-methoxyphenyl)(phenyl)methylaminooxy)-3-methyl-5oxopenta-1,3-dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE18)
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The title compound was obtained in 83% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.91-7.96 (m, 1H), 7.53 (d, J = 7.5 Hz, 1H), 7.40-7.45 (m, 6H), 7.03
(t, J = 7.2 Hz, 1H), 6.87 (d, J = 8.4 Hz, 1H), 6.19 (d, J = 16.2 Hz, 1H), 5.94 (s, 1H),
5.74 (s, 1H), 3.56 (s, 3H), 2.26-2.51 (m, 2H), 2.11 (s, 1H), 2.06 (s, 3H),
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1.92 (s, 3H),

1.11 (s, 3H), 1.02 (s, 3H). 13C NMR (75.5 MHz, CDCl3) δ (ppm): 197.4, 163.5, 162.1,
157.9, 151.2, 136.8, 133.6, 131.3, 131.0, 129.3, 128.7, 128.1, 127.6, 126.9, 120.4, 115.7,
111.5, 79.4, 55.4,

49.6, 41.3, 24.1, 22.8, 21.1, 18.6. TOF-HRMS (m/z) found (calcd.)

for C29H33NO5 (M): [M+Na]+, 498.2253 (498.2256).

(4S)-4-((1E,3Z)-5-((4-methoxyphenyl)(phenyl)methylaminooxy)-3-methyl-5oxopenta-1,3-dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE19)

The title compound was obtained in 81% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.94 (d, J = 16.2 Hz, 1H), 7.59-7.26 (m, 7H), 6.96 (d, J = 12.0 Hz, 2H
for isomer 1), 6.86(d, J = 12.0 Hz, 2H for isomer 2), 6.20 (d, J = 16.2 Hz, H for isomer
1), 6.19 (d, J = 16.2 Hz, 2H for isomer 2), 5.92 (s, 1H), 5.68(s, 1H for isomer 1), 5.58
(s, 1H for isomer 2), 3.87 (s, 3H for isomer 1), 3.82 (s, 3H for isomer 2), 2.49-2.28 (m,
2H), 2.04 (s, 3H for isomer 2), 2.01 (s, 3H for isomer 1), 1.91 (s, 3H),1.10 (s, 3H), 1.00
(s, 3H). The ratio between isomer 1 and 2 is 2.1:1.
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C NMR (75.5 MHz, CDCl3) δ

(ppm): 197.5, 164.1,163.4, 162.2,160.4,151.3,137.0, 135.3, 131.0, 130.5, 135.4, 129.2,
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128.6, 128.1, 128.0, 127.0, 124.5, 115.7, 113.6, 113.3, 79.9, 55.2, 49.6, 41.4, 24.2, 22.9,
21.2, 18.7. TOF-HRMS (m/z) found (calcd.) for C29H31NO5 (M): [M+H]+, 474.2280
(474.2280); [M+Na]+, 496.2100 (496.2100) and [M+K]+, 512.1825 (512.1839).

(4S)-4-((1E,3Z)-5-((4-chlorophenyl)(phenyl)methylaminooxy)-3-methyl-5oxopenta-1,3-dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE20)

The title compound was obtained in 78% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.92 (d, J = 16.2 Hz, 1H), 7.58-7.26 (m, 9H), 6.22 (d, J = 16.2 Hz, 1H
for isomer 1),6.21 (d, J = 16.2 Hz, 1H for isomer 2), 5.90 (s, 1H), 5.30(s, 1H for isomer
1), 5.29 (s, 1H for isomer 2), 2.49-2.28 (m, 2H), 2.01 (s, 3H for isomer 2), 2.00 (s, 3H
for isomer 1), 1.91 (s, 3H),1.10 (s, 3H), 1.00 (s, 3H). The ratio between isomer 1 and 2
is 1:1.2. 13C NMR (75.5 MHz, CDCl3) δ (ppm): 197.8, 163.5, 163.4, 162.2, 152.2, 137.2,
135.8, 134.6, 133.5, 132.3, 131.2, 130.5, 130.4, 129.9, 129.1, 129.0, 128.9, 128.8, 128.7,
128.6, 128.4, 128.2, 127.2, 115.5, 79.7, 49.9, 41.7, 24.4, 23.2, 21.4, 19.0. TOF-HRMS
(m/z) found (calcd.) for C28H28ClNO4 (M): [M+H]+, 478.1778 (478.1785); [M+Na]+,
496.2100 (496.2100) and [M+K]+, 512.1825 (512.1839).
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(S)-4-((1E,3Z)-5-(bis(4-chlorophenyl)methylaminooxy)-3-methyl-5-oxopenta-1,3dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE21)

The title compound was obtained in 91% yield as yellow solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.92 (d, J = 16.2 Hz, 1H), 7.56-7.24 (m, 8H), 6.24 (d, J = 16.2 Hz)
5.90 (s, 1H), 5.61 (s, 1H), , 2.50-2.30 (m, 2H), 2.03 (s, 3H for isomer 2), 1.92 (s, 3H for
isomer 1), 1.91 (s, 3H),1.11 (s, 3H), 1.02 (s, 3H). 13C NMR (75.5 MHz, CDCl3) δ (ppm):
197.8, 163.2, 162.4, 152.5, 147.4, 137.7, 136.0, 133.1, 130.6, 130.4, 130.3, 129.1, 128.9,
128.1, 127.3, 115.2, 79.7, 49.8, 41.7, 24.4, 23.2, 21.5, 19.0. TOF-HRMS (m/z) found
(calcd.) for C28H27Cl2NO4 (M): [M+H]+, 512.1402 (512.1395); [M+Na]+, 534.1239
(534.1215).

(4S)-4-hydroxy-4-((1E,3Z)-5-((4-methoxyphenyl)(phenyl)methylaminooxy)-3methyl-5-oxopenta-1,3-dienyl)-3,5,5-trimethylcyclohex-2-enone (ABA-FE22)
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The title compound was obtained in 85% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.79-7.91 (m, 2H), 7.28-7.45 (m, 7H), 6.86 (d, J = 8.7 Hz, 2H), 6.15
(d, J = 16.2 Hz, 1H), 5.95 (s, 1H), 5.68 (s, 1H), 5.20 (s, 1H), 3.89 (s, 3H), 2.28-2.51 (m,
2H), 2.13 (s, 1H), 1.91-2.01 (m, 6H), 1.11 (s, 3H), 1.00 (s, 3H). 13C NMR (75.5 MHz,
CDCl3) δ (ppm): 197.3, 166.2, 162.0, 159.2, 150.4, 136.9, 129.0, 128.5, 127.9, 127.6,
127.1, 115.6, 114.0, 79.5, 68.6, 55.2, 49.7, 41.4, 24.3, 23.0, 21.3, 18.7. TOF-HRMS
(m/z) found (calcd.) for C29H33NO5 (M): [M+H]+, 476.2447 (476.2437); [M+Na]+,
498.2260 (498.2256) and [M+K]+, 514.2013 (514.1996).

(4S)-4-((1E,3Z)-5-((4-chlorophenyl)(phenyl)methylaminooxy)-3-methyl-5oxopenta-1,3-dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE23)

The title compound was obtained in 88% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm) 7.79-7.98 (m, 2H), 7.28-7.62 (m, 9H), 6.16 (d, J = 16.2 Hz, 1H),
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5.96 (s, 1H), 5.67 (s, 1H), 5.29 (s, 1H), 2.28-2.51 (m, 2H), 1.92-2.06 (m, 7H), 1.13 (s,
3H), 1.01 (s, 3H). TOF-HRMS (m/z) found (calcd.) for C28H30ClNO4 (M): [M+H]+,
480.1925 (480.1942).

(S)-4-((1E,3Z)-5-(bis(4-chlorophenyl)methylaminooxy)-3-methyl-5-oxopenta-1,3dienyl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE24)

The title compound was obtained in 77% yield as yellow solid. 1H NMR (300
MHz, CDCl3) δ (ppm) 7.84-7.89 (m, 2H), 7.28-7.57 (m, 8H), 6.16-6.22 (m, 1H), 5.96
(s, 1H), 5.67 (s, 1H), 5.17 (s, 1H), 2.29-2.51 (m, 2H), 1.92-2.07 (m, 7H), 1.13 (s, 3H),
1.01 (s, 3H). 13C NMR (75.5 MHz, CDCl3) δ (ppm): 197.4, 166.0, 162.0, 150.6, 136.9,
130.5, 129.2, 128.7, 127.7, 127.5, 126.9, 115.1, 79.4, 68.1, 49.5, 41.3, 24.1, 22.8, 21.1,
18.7. TOF-HRMS (m/z) found (calcd.) for C28H29Cl2NO4 (M): [M+Na]+, 536.1348
(536.1371).

(4S)-4-((1E,3Z)-5-(((2,2-dimethyl-1-phenylpropyl)amino)oxy)-3-methyl-5oxopenta-1,3-dien-1-yl)-4-hydroxy-3,5,5-trimethylcyclohex-2-enone (ABA-FE25)
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The title compound was obtained in 65% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 7.46-7.48 (m, 2H), 7.29-7.32 (m, 3H), 7.04-7.17(m, 1H), 6.18 (dd, J =
6.6 Hz, 12.0 Hz, 1H), 5.86 (s, 1H), 5.90 (s, 1H), 4.64 (s, 1H), 2.22-2.40 (m, 2H), 2.04
(s, 1H), 1.98(s, 3H), 1.82(d, J = 12.0 Hz, 3H), 1.04-1.07(m, 12H), 0.91(d, J = 12.0 Hz,
3H). TOF-HRMS (m/z) found (calcd.) for C26H35NO4 (M): [M+H]+, 426.2649
(426.2644); [M+Na]+, 448.2466 (448.2464) and [M+K]+, 464.2211 (464.2203).

4S)-4-hydroxy-4-((1E,3Z)-5-(1-(4-methoxyphenyl)-2,2-dimethylpropylaminooxy)-3methyl-5-oxopenta-1,3-dienyl)-3,5,5-trimethylcyclohex-2-enone (ABA-FE26)

The title compound was obtained in 79% yield as white solid. 1H NMR (300 MHz,
CDCl3) δ (ppm) 8.25 (s, 1H), 7.73-7.81 (m, 1H), 7.25-7.38 (m, 2H), 6.86-6.91 (m, 2H),
6.16 (d, J = 16.2 Hz, 1H), 5.94 (s, 1H), 5.58 (s, 1H), 3.82 (s, 3H), 3.76 (s, 1H), 2.282.50 (m, 2H), 1.87-2.06 (m, 7H), 1.13 (s, 3H), 0.99 (s, 12H), 0.91 (s, 3H). 13C NMR
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(75.5 MHz, CDCl3) δ (ppm): 197.5, 166.3, 162.2, 158.7, 149.8, 136.7, 131.2, 129.7,
129.5, 127.8, 127.0, 115.7, 113.2, 112.9, 79.5, 73.2, 55.1, 49.7, 41.4, 34.3, 33.9, 27.2,
24.1, 23.0, 21.1, 18.8. TOF-HRMS (m/z) found (calcd.) for C27H37NO5 (M): [M+H]+,
456.2744 (456.2750); [M+Na]+, 478.2566 (478.2569) and [M+K]+, 494.2298
(494.2309). TOF-HRMS (m/z) found (calcd.) for C27H37NO5 (M): [M+H]+,456.2744
(456.2750); [M+Na]+, 478.2566 (478.2569) and [M+K]+, 494.2298 (494.2309).
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Chapter 4
A Self-Reporting Chemically Induced Protein Proximity System
Based on a Malachite Green Derivative and the L5** Fluorogen
Activating Protein
(This chapter is based on a manuscript in preparation)

4.1 Introduction

The

chemically

induced

proximity

(CIP),

or

chemically

induced

dimerization (CID), method uses a small molecule inducer that homo- or heterodimerizes two unique inducer-binding protein domains fused individually to any
two proteins of interest (POIs). Depending on the choice of linked POIs, a variety
of downstream cellular events can be triggered temporally by the chemical
inducer.1-4 Several CIP systems have been engineered that each uses a unique
chemical inducer to dimerize a corresponding pair of inducer-binding proteins.514

These orthogonal CIP systems allow multiple biological events to be controlled

simultaneously and independently in the same cell and the construction of
sophisticated bio-computation systems.15 Recently, several studies have shown
that these CIP inducers can be chemically modified to become activatable by
artificial or endogenous cellular signals that greatly expands the utility of CIP
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methods in synthetic biology.16-21 One limitation of existing CIP systems is that
the inducer-triggered dimerization cannot be directly monitored, therefore, the
kinetics of dimerization and that between dimerization and the induced
downstream effects is difficult to follow.

Fluorogen activating proteins (FAPs) derived from single chain antibodies
(scFv) induce fluorescent signals upon binding from certain organic dyes
(fluorogens) which are otherwise non-fluorescent when free in solution.22-28
Structural studies of the malachite green (MG-based FAP system revealed that
MG forms a 1:2 ligand:protein complex with two L5** proteins, the VL domain
of an antibody, which leads to the activation of intense fluorescence.29
Importantly, these L5** protein domains do not self-dimerize in the absence of
dye, and association is induced in the presence of fluorogenic dye.

We reason

that by linking two POIs individually to each L5** protein, a new MG inducible
CIP system can be built that can trigger downstream effects through MG-induced
VL-POI dimerization and also self-report the dimerization by activation of MG
fluorescent signals upon dimerization, producing a self-reporting chemically
induced proximity system (Figure 4.1).
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Figure 4.1 MG-based chemically induced proximity method to control biological
processes.

4.2 MG-based fluorogenic CIP system to induce transcriptional activation

To create an MG-based fluorogenic CIP system, we first constructed an MG
inducible transcriptional activation system based on L5**-fusion proteins
(Figure 4.2). We generated DNA plasmids encoding the MG-inducible gene
expression cassette including a yeast Gal4 DNA binding domain (Gal4DBD)L5** and a herpes simplex virusVP16 transactivation domain (VP16AD)-L5**
fusion proteins. A reporter construct with five copies of the upstream activation
sequence (UAS) that Gal4DBD recognizes inserted upstream of a luciferase gene
was used to test the transcriptional activation. In this system, luciferase
expression can be turned on only when MG induces hetero-dimerization of
GAL4DBD-L5** and L5**-VP16AD. Furthermore, fluorescence will be
observed only when MG forms a complex with two L5** fusion proteins.
Although the homo-dimerization of two identical L5** fusion proteins can also
induce MG fluorescence, we expect that any activated fluorescence will report
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combined occurring dimerization events from both hetero- and homodimerizations and provide the information regarding the dimerization kinetics.

Figure 4.2 Scheme and constructs of MG-induced luciferase expression system.

To test this system, we co-transfected HEK293T cells with the MG-inducible
gene expression cassette and the UAS-luciferase reporter (Figure 4.2) for 24 h
and then treated cells with 500 nM MG and two MG derivatives, a cell-permeant
MGnBu30 and cell-excluded MG-B-Tau,31 (Figure 4.3) for another 24 h. Under
these conditions, the cell excluded MG-B-Tau would be expected to stimulate no
protein proximity, while the cell permeant analogs MG and MGnBu could induce
protein interactions and drive reporter expression.
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Figure 4.3 Structures of MG, MGnBu and MG-B-Tau

Resulting cells were washed and analysed under a fluorescence plate reader to
detect the activated MG fluorescence (excitation 640 nm/ emission 670 nm), or
lysed for luciferase assays. A 30-fold (for MG-B-Tau) to 250-fold (for MGnBu)
fluorescence increase from activated MG fluorescence can be observed (Figure
4.4), as well as a 3-fold increase in luciferase expression in the case of MGnBu
induction (Figure 4.5). This study showed that an MG-based fluorogenic CIP
system can be established and the observed activated MG fluorescence is
correlated with the observed induced luciferase expression. The low induction
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fold in luciferase expression is likely a result of the competition between the
hetero- and homo-dimerization of GAL4DBD-L5** and L5**-VP16AD. Since
MGnBu gave the highest fluorescent signal upon dimerization and induced the
highest level of luciferase expression, we focused on MGnBu as the inducer for
the following studies.

Figure 4.4 Activated MG fluorescence fold changes in HEK293T cells by MG,
MGnBu and MG-B-Tau. The cells were transfected with the constructs shown in Figure
4.2 for 24 h before addition of 500 nM MG or MGnBu or MG-B-Tau for another 24 h.
Cells were washed and analyzed by fluorescence plate reader. The induced fold change
was calculated by comparison to the values of ethanol-treated samples. Independent
experiments were repeated five or more times. Errors bars are SD (N=5).
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Figure 4.5 Induced luciferase expression in HEK293T cells by MG, MGnBu and MGB-Tau. The cells were transfected with the constructs shown in Figure 4.2 for 24 h
before addition of 500 nM MG or MGnBu or MG-B-Tau for another 24 h. Cells were
washed and analyzed by luciferase assays. The induced fold change was calculated by
comparison to the values of ethanol-treated samples. Independent experiments were
repeated five or more times. Errors bars are SD (N=5).

We next tested if there is dosage dependence in this new MG-based CIP system as
seen in other CIP systems. We transfected HEK293T cells with the MG-inducible gene
expression cassette and the UAS-luciferase reporter for 24 h, and then treated cells with
MGnBu (from 0 to 1000 nM) for another 24 h. We observed that activated MGnBu
fluorescence showed a dosage-dependent increase and gave the highest signal at 500
nM (Figure 4.6). A similar dosage-dependent increase was observed in luciferase
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induction, which also reached the highest expression at 500 nM (Figure 4.7).

Figure 4.6 Dosage response of activated MGnBu fluorescence fold change in
HEK293T cells. The cells were transfected with the constructs shown in Figure 4.2 for
24 h before addition of 0-1000 nM of MGnBu for another 24 h. Cells were washed and
analyzed by fluorescence plate reader. The induced fold change was calculated by
comparison to the values of ethanol-treated samples. Independent experiments were
repeated five or more times. Errors bars are SD (N=5).
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Figure 4.7 Dosage response of induced luciferase expression in HEK293T cells. The
cells were transfected with the constructs shown in Figure 4.2 for 24 h before addition
of 0-1000 nM of MGnBu for another 24 h. Cells were washed and analyzed by
luciferase assays. For The induced fold change was calculated by comparison to the
values of ethanol-treated samples. Independent experiments were repeated five or more
times. Errors bars are SD (N=5).

4.3 MG-based fluorogenic CIP system to control protein translocation

Next, we tested if the MG-induced CIP system can be used to control protein
translocation. We constructed DNA plasmids encoding the nuclear export sequencetagged L5** (NES-L5**) and the EYFP-L5** fusion proteins (Figure 4.8).

Figure 4.8 DNA constructs for EYFP translocation experiments.
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We transfected CHO cells with both constructs for 24 h and followed by treating
cells with 500 nM MGnBu (or ethanol as a negative control). Cells were then collected
at different time points after MGnBu addition for analysis of MGnBu fluorescence
activation and EYFP-L5** translocation. We quantified the fold changes of activated
MGnBu fluorescence due to dimerization with a fluorescence plate reader. We observed
a rapid and significant increase in fluorescence of MGnBu within 5 min, which
continued to increase during the observation time period up to 4 h (Figure 4.9).

Figure 4.9 Time course (0 to 4 h) of activated MGnBu fluorescence fold change. Cells
were transfected with the constructs in Figure 4.8 for 24 h before treating with 500 nM
MGnBu for indicated time periods. Then cells were washed and collected for analysis
by fluorescence plate reader.

Meanwhile, the subcellular distribution of EYFP-L5** proteins was monitored
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under a fluorescence microscope. When expressed in the cell, EYFP-L5** proteins
were found to freely cross the nuclear envelope, and distributed throughout the cell
although a preferential nuclear localization was observed (Figure 4.10-i). In the
presence of MGnBu, the dimerization between of EYFP-L5** and NES-L5** led to an
obvious translocation of EYFP-L5** out of the nucleus (Figure 4.10-ii). Such nuclear
exclusion is due to the association of EYFP with NES after MGnBu heterodimerization
between EYFP-L5** and NES-L5** instead of the increased size of the homodimerized
EYFP-L5** because the same EYFP translocation was not observed when cells were
transfected only with EYFP-L5** and treated with MGnBu (Figure 4.11).

Figure 4.10 Representative EYFP images of transfected CHO cells without MGnBu
(i), with 500 nM MGnBu (ii), or removal of MGnBu after treatment (iii). Scale bar is
50 µm.
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Figure 4.11 Representative images for: CHO cells were transfected with 0.2 μg SV40EYFP-L5** only or with 0.4 μg SV40-NES-L5** for another 24 hours. Cell were
treated with ethanol or with 500 nM of MGnBu for 24 hours.

We quantified the degree of MGnBu-induced EYFP-L5** translocation by first
calculating an EYFP-L5** nuclear-distribution ratio defined by the EYFP fluorescence
intensity inside versus outside the nucleus in non-MGnBu-treated cells (100 – 200
random cells counted along the diagonal of each field of view from 5 fields total). After
MGnBu treatment, the same EYFP-L5** nuclear-distribution ratio value was
determined for each cell (100 – 200 random cells counted in each condition), and the
number of cells showing a lower nuclear-distribution ratio value (defined as nuclear
exported or translocated) was calculated and the percentage of translocated cells over
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the total counted cells was determined at each indicated time point after MGnBu
addition. We observed a rapid translocation of EYFP-L5** into cytoplasm (Figure 4.12)
and the kinetics of the activated MGnBu fluorescence is well correlated with the
kinetics of induced protein translocation.

Figure 4.12 The percentage of cells showing induced EYFP translocation in transfected
CHO cells treated with MGnBu (0 to 4 h). Cells were transfected with the constructs in
Figure 4.8 for 24 h before treating with 500 nM MGnBu for indicated time periods.
Then cells were observed under a fluorescence microscope. The statistical data were
obtained by counting cells showing EYFP translocation over the total EYFP positive
cells to give the percentage of translocated cells. Cells were counted from three separate
experiments, and 100-200 cells were counted for each sample. Error bars are SD (N =
3).

To investigate whether the MG-induced CIP system is reversible, after CHO cells
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were transfected with EYFP-L5** and NES-L5** constructs and treated with MGnBu
for 4 h, cells were washed with fresh media (without MGnBu) for 3 times and collected
for analysis at different time points after the withdrawal of MGnBu. The activated
MGnBu fluorescence fold change and the percentage of cells showing cytoplasmic
translocation were quantified as described above. We observed that both the activated
MGnBu fluorescence and the induced EFYP-L5** translocation was readily reversible
and well-correlated with each other (Figures 4.13 and 4.14).

Figure 4.13 Time course (0 to 4 h) of activated MGnBu fluorescence fold change after
MGnBu withdrawal in transfected CHO cells originally treated with MGnBu. After
indicated time, cells were washed and collected for analysis by fluorescence plate
reader.
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Figure 4.14 Time course (0 to 4 h) of the percentage of cells showing induced EYFP
translocation after MGnBu withdrawal in transfected CHO cells originally treated with
MGnBu. The statistical data were obtained by counting cells showing EYFP
translocation over the total EYFP positive cells to give the percentage of translocated
cells. Cells were counted from three separate experiments, and 100-200 cells were
counted for each sample. Error bars are SD (N = 3).

4.4 orthogonal test to other existing CIP systems

Finally, we tested whether this new MG-based CIP system is orthogonal to other
existing CIP systems including abscisic acid (ABA)-based system that dimerizes
ABI/PYL fusion proteins,13 gibberellin acid (GA)-based system that dimerizes
GAI/GID1 fusion proteins,14 and rapamycin (Rap)-based system that dimerize
FRB/FKBP fusion proteins.5 We constructed a new plasmid encoding GA-inducible
transcriptional activation cassette (Figure 4.15-iii) and used the MG, ABA and Rap
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inducible constructs that were developed in this study or previously (Figure 4.15).

Figure 4.15 DNA constructs for inducible gene expression induced by (i) MGnBu, (ii)
ABA, (iii) GA, (iv) Rap.

We co-transfected CHO cells with a UAS luciferase reporter and individually with
each of these inducible transcriptional activation cassettes for 24 h. MGnBu, GA-AM,
ABA, Rap or ethanol (negative control) was then separately added to each transfected
condition for another 24 h. Afterwards, cells were collected and analysed by a
fluorescence plate reader for activated inducer fluorescence or by luciferase assays for
induced luciferase expression. We observed that only cells transfected with the MGinducible cassette and treated with MGnBu gave detectable fluorescence signals
(Figure 4.16). We also confirmed that these four tested CIP systems are orthogonal in
that only the corresponding inducer can dimerize the matching fusion protein pairs to
induce luciferase expression (Figure 4.17). The MGnBu induced CIP system is the only
method that allows direct monitoring the induced dimerization and also triggering
downstream cellular effects.
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Figure 4.16 Activated inducer fluorescence fold change after transfected HEK293T
cells were treated by different CIP inducers for 24 h. For all experiments, the induction
fold change was calculated relative to the values of non-induced (i.e. ethanol treated)
samples. Independent experiments were repeated five or more times. Errors bars are
SD (N=5).
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Figure 4.17 Induced luciferase expression after transfected HEK293T cells were
treated by different CIP inducers for 24 h. For all experiments, the induction fold
change was calculated relative to the values of non-induced (i.e. ethanol treated)
samples. Independent experiments were repeated five or more times. Errors bars are
SD (N=5).

4.5 Conclusions

In summary, we developed a unique new fluorogenic CIP system that uses an
MG derivative (MG-nBu) as an inducer that is able to trigger specific
downstream cellular events through the dimerization of two L5** fusion proteins
and also generates fluorescence signal upon forming the ternary. This is the first
CIP system that is able to achieve direct reporting of dimerization. Although the
induced effects are not as high as other CIP systems that dimerize two nonidentical inducer-binding proteins, we expect that new FAP-based MG binding
proteins can be engineered to offer new and improved fluorogenic CIP systems
with specific heterodimerization.

In addition to the range of MG-analog

binding FAP proteins, a variety of additional fluorogens with cognate fluorogen
activating proteins, several of which have been found to form ternary complexes
sandwiching a single ligand suggests that a range of additional CIP systems could
be derived from FAP-fluorogen pairs.27, 32
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4.6 Methods

4.6.1 Cloning and plasmid construction

All DNA fragments were amplified by PCR (Polymerase chain reaction) from other
intermediate constructs with the enzyme of Phusion DNA Polymerase (New England
Biolabs) under S1000 thermal cycler with Dual 48/48 Fast Reaction Module (Bio-Rad).
All the restriction enzymes used below are purchased from New England Biolabs. All
the constructs with L5** were amplified using pcDNA3.1-KozATG-dL5-2XG4SmCer3 (plasmid #73207 from Addgene) as the template.

Actin-VP-L5**-ires-Gal-L5** was derived from SV40-VP-PYL-ires-Gal-ABI by
replacing PYL to L5** using AscI and BamHI sites (amplified by primers
CCGACAGGCGCGCCACAGGCCGTCGTTACCCAAGAA and CCGACAGGATC
CTCAAGCGTAATCTGGAACATCGTATGGGTAGGACAGAACCGTCAGTTGTG
T), replacing ABI to L5** using MluI and NotI sites (amplified by primers
CCGACAACGCGTCAGGCTGTGGTGACTCAGGAG and CCGACAGCGGCCG
CTTCACTTGTCGTCATCGTCTTTGTAGTCGGAGAGGACGGTCAGCTGGGT),
and then replacing SV40 to Actin using SpeI and EcoRI sites (insert restricted from
Actin-EGFP-PYL 2i).

SV40-NES-L5** was generated from SV40-VP-PYL-ires-Gal-ABI by replacing
VP-PYL-ires-Gal-ABI to NES-L5** using EcoRI and NotI sites (amplified by primers
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CCGACAGAATTCGCCACCATGCTTCCTCCACTAGAACGTCTGACTCTGGAT
GGATCCCAGGCTGTGGTGACTCAGGAG and CCGACAGCGGCCGCTTCACT
TGTCGTCATCGTCTTTGTAGTCGGAGAGGACGGTCAGCTGGGT).

SV40-EYFP-L5** was generated from SV40-VP-PYL-ires-Gal-ABI by replacing
ABI to L5** using MluI and NotI sites (amplified primers are the same as the ones
when making Actin-VP-L5**-ires-Gal-L5**), and replacing VP-PYL-ires-Gal to
EYFP

using

EcoRI

and

MluI

sites

(amplified

by

primers

CCGACAGAATTCATGGTGAGCAAGGGCGAGGAGCTG and CCGACAACGC
GTCTTGTACAGCTCGTCCATGCC, template YFP-GID1 from Addgene #37305).

SV40-VP-GAI-ires-Gal-GID1 was generated from SV40-VP-PYL-ires-Gal-ABI
by replacing PYL to GAI using AcsI and BamHI sites (amplified by primers
CCGACAGGCGCGCCAGGATCTGGTGGAAAGAGAGATCATCATCATCAT and
CCGACAGGA TCCTCAAGGATTAAGGTCGGTGAGCAT), and replacing ABI to
GID1

using

MluI

and

NotI

sites

(amplified

by

CCGACAACGCGTGGATCTGGTGGAGCTGCGAGCGATGAAGTTAAT
CCGACAGCGGCCGCTCAACATTCCGCGTTTACAAACGC).

Templates

primers
and
were

Actin-4XNLS-GID1 and Actin-GAI-ABI 4b.

4.6.2 Mammalian cell culture and transfection

All cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS,
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2 mM GlutaMAX (life technologies), 100 U/ml penicillin (life technologies) and 100
μg/ml streptomycin (life technologies) at 37℃ in a humidified atmosphere containing
5% CO2.

Fluorescence micro plate reader quantification and luciferase activity
quantification. (1) For compounds screening and dosage dependent experiments,
HEK293T cells were seeded in 24-well plate at 100,000/well for 24 hours and then
transfected with 0.4 µg of Actin-VP-L5**-ires-Gal-L5** & 0.2 µg of 5XUASluciferase and waited for another 24 hours. Then, cells were treated with ethanol or 500
nM of MG or MGnBu or MG-B-Tau, or treated with 0 nM to 1000 nM of MGnBu.
After 24 hours, cells were harvested and washed with PBS twice, and resulting cells
were re-suspended in 100 µL of PBS and fluorescence was quantified by fluorescent
plate reader (ex/em 640 nm/670 nm). Meanwhile, cells samples with the same
conditions were harvested and quantified with the luciferase activity. (2) For
experiments testing orthogonality with different CIP systems, HEK293T cells were
seeded in 24-well plate at 100,000/well for 24 hours and then transfected with 0.2 µg
of 5XUAS-luciferase together with 0.4 µg of Actin-VP-L5**-ires-Gal-L5**, or SV40VP-PYL-ires-Gal-ABI, or SV40-VP-GAI-ires-Gal-GID1, or SV40-VP-Frb-ires-Gal3FKBP, for another 24 hours. And then cells treated with ethanol, or 500 nM MGnBu,
or 10 µM ABA, 100 µM GA-AM, 10 nM rap. After 24 hours, cells were harvested and
washed with PBS twice, and resulting cells were re-suspended in 100 µL of PBS and
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fluorescence was quantified by fluorescent plate reader. Meanwhile, cells samples with
the same conditions were harvested and quantified the luciferase activity. All cellular
experiments were conducted 3 to 4 independent times and each time with triplicate or
quadruplicate.

Protein translocation. CHO were seeded over glass coverslips in 24-well plates at
50,000/well for 24 hours. Then cells were transfected with 0.2 μg SV40-EYFP-L5**
and 0.4 μg SV40-NES-L5** for another 24 hours. Cell were treated with ethanol or
with 500 nM of MGnBu for 5 min, 15 min, 30 min, 1 hour, 2 hours and 4 hours. After
indicated time, cells were fixed with 4% paraformaldehyde and mounted on a glass
slide with Vectashield (VWR) mounting media and images of cells were then taken by
using a fluorescence microscope. For drug withdrawal experiments, after treatment
with 500 nM of MGnBu for 4 hours, cells were washed with warm and fresh medium
for three times (5 mins for between each wash) and then incubated with 15 min, 30 min,
1 hour and 2 hours. After indicated time, cells were fixed to make the cover slides and
images were taken by using a fluorescence microscope. For all conditions, in the
meanwhile of making the coverslips, cells samples with the same conditions were
harvested and fluorescence was quantified by fluorescent plate reader (ex/em 640
nm/670 nm). All cellular experiments were conducted 3 to 4 independent times and
each time with triplicate or quadruplicate.

4.6.3 Fluorescence microscopy
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Zeiss Axio Observer. D1 outfitted with HBO 100 microscopy illumination system
(excitation 470/40 and emission 525/50) was used for Ruffle formation experiments.
Fluorescent channels in all experiments were adjusted to the same intensity ranges.
Acquisition times ranged from 50 to 500 ms.

4.6.4 Statistical analysis of cell population

To determine the translocation of EYFP upon the drug treatment, first we measured
the fluorescence intensity ratio of nucleus/cytoplasm for the cells without drug
treatment, to get the ratio range (mean initial±SD). After treatment with MGnBu for
indicated time, we measured the fluorescence intensity ratio of nucleus/cytoplasm for
the cells, and identified the cells with translocation when the fluorescence intensity ratio
of nucleus/cytoplasm was lower than the lowest ratio (mean initial-SD). And percentage
of the cells with EYFP translocation was calculate by numbers of translocation cells
over total cells number.

In a similar way, we quantified the reversibility of the EYFP translocation process.
First, we measured the fluorescence intensity ratio of nucleus/cytoplasm for the cells
before the drug withdrawal, to get the ratio range (mean treatment±SD). After wash
with medium and incubated with different time, we measured the fluorescence intensity
ratio of nucleus/cytoplasm for the cells, and identified the cells with translocation
reversible when the fluorescence intensity ratio of nucleus/cytoplasm was higher than
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the highest ratio (mean treatment + SD).

Cell images were collected from 5 different areas (4 quarters and center) in each of
the 3 independent experiments. For each condition, 110 to 200 cells were analyzed
along the diagonal lines. Mean fluorescence of nucleus and cytoplasm were analyzed
by using Image J and get the ratio of these two for each analyzed cell.
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